

Antiseizure medication Exposure and Pregnancy and neonatal outcomes research: ADEPT

**The utilisation of antiseizure medications in
pregnant women, and women and men of
childbearing age: a multi-database study from 6
European countries**

Protocol v4.0, 03 Jun 2026

Title	The utilisation of antiseizure medications in pregnant women, and women and men of childbearing age (ADEPT): a multi-database study from 6 European countries
Protocol version identifier	4.0
Date of last version of protocol	3 June 2026
EU PAS number	EUPAS1000000212
Active substance	Methylphenobarbital, phenobarbital, primidone, barbexaclone, metharbital, ethotoin, phenytoin, amino(diphenylhydantoin) valeric acid, mephenytoin, fosphenytoin, paramethadione, trimethadione, ethadione, phensuximide, mesuximide, ethosuximide, clonazepam, carbamazepine, oxcarbazepine, rufinamide, valproic acid, valpromide, aminobutyric acid, vigabatrin, progabide, sultiame, phenacemide, lamotrigine, felbamate, topiramate, pheneturide, levetiracetam, zonisamide, stiripentol, lacosamide, carisbamate, retigabine, perampanel, brivaracetam, cenobamate, fenfluramine, ganaxolone, beclamide, gabapentin, pregabalin, mirogabalin, eslicarbazepine, diazepam, lorazepam, clobazam, midazolam.
Medicinal product	(See above)
Product reference	n/a
Procedure number	n/a
Marketing authorisation holder(s)	n/a
Research question and objectives	This will be a drug utilisation study for antiseizure medications (ASMs) in pregnant women, and women and men of childbearing age, using data from 8 electronic healthcare databases in 6 European countries. This main objective has the following sub-objectives: Objective 1.1 To estimate the annual incidence and prevalence rate of ASM use in women (12-55 years old) and men (≥ 12 years old) of childbearing age; Objective 1.2 To describe treatment duration, discontinuation, and treatment switches of ASMs to other ASMs or alternative medications and polytherapy in women and men of childbearing age; Objective 1.3 To estimate pre-pregnancy ASM use, and initiation and continuous use of ASMs during pregnancy period; Objective 1.4 To estimate pre-pregnancy, early and late discontinuation of ASMs, treatment switches to other ASMs or alternative medications and polytherapy among pregnant women; Objective 1.5 To estimate dose changes of ASMs in women prior to and during pregnancy.
Countries of study	Finland, France, Italy, Norway, Spain, the United Kingdom
Authors	Shahab Abtahi Carlos Durán Salinas Magdalena Gamba Elizabeth Comberg Si Han Miriam Sturkenboom
Reviewers	All consortium (or at least one person from each centre) has reviewed the draft protocol. Please see the table in section 5.1 Investigators.

Table of Contents

Table of Contents.....	3
1 Title.....	5
2 Abbreviations.....	5
3 Marketing Authorisation Holder.....	6
4 Responsible Parties	6
4.1 Investigators.....	6
5 Abstract.....	8
6 Amendments and Updates	9
7 Milestones	10
8 Rationale and Background.....	11
9 Research Question and Objectives.....	12
10 Research Methods.....	13
10.1 Study design.....	13
10.2 Study setting.....	13
10.3 Source and study population.....	14
10.4 Variables	17
10.4.1 Exposure	17
10.4.2 Drug utilisation outcomes	22
10.4.3 Covariates	24
10.5 Data sources	25
10.5.1 Spain (ES): VID (Valencia).....	25
10.5.2 Spain (ES): SIDIAP (Catalonia)	25
10.5.3 Norway (NO): Norwegian data registries	26
10.5.4 United Kingdom (UK): CPRD.....	26
10.5.5 Finland (FI): Finnish Health Registries	26
10.5.6 France (FR): EFEMERIS.....	27
10.5.7 Italy (IT): VAL PADANA LHU.....	28
10.5.8 SPAIN (ES): BIFAP	28
10.6 Study size.....	29
10.7 Data management.....	29
10.8 Data analysis	31
10.9 Quality control	39
10.10 Limitations of the research methods	40
10.10.1. Limitations related to data sources	40
10.10.2. Limitations in proposed methodology	41

11	Protection of Human Subjects	41
12	Management and Reporting of Adverse Events/Reactions	42
13	Plans for Disseminating and Communicating Study Results	42
14	References.....	43

1 Title

The utilisation of antiseizure medications in pregnant women, and women and men of childbearing age (ADEPT): a multi-database study from 6 European countries

2 Abbreviations

List of abbreviations

Abbreviation	Explanation
AEMPS	Spanish Agency of Medicines and Medical Devices
ARS	Agenzia regionale di sanità della Toscana
ASM	Antiseizure medications
BIFAP	Base de datos para la Investigación Farmacoepidemiológica en el Ámbito Público
BPE	Bordeaux PharmacEpi platform
CHUT	Centre Hospitalier Universitaire de Toulouse
CDM	Common data model
CI	confidence interval
CPRD	Clinical Practice Research Datalink
CONSIGN	Covid-19 infectiON and medicineS In pregnancy
DAP	Data Access Provider (Partner)
DDD	Defined daily dose
EFEMERIS	Evaluation chez la Femme Enceinte des MEDicaments et de leurs RISques
EHR	electronic health records
EMA	European Medicines Agency
ENCePP	European Network of Centres for Pharmacoepidemiology and Pharmacovigilance
ETL	Extract transform load
EU PAS Register	European Union Electronic Register of Post-Authorisation Studies
EU PE&PV	European Pharmacoepidemiology & Pharmacovigilance research network
FISABIO	Foundation for the Promotion of Health and Biomedical Research in the Valencian Community
GPP	Good Pharmacoepidemiology Practices
GVP	Good Pharmacovigilance Practices
HES	Hospital episode statistics
HCU	health care utilisation
ICPC-2	<i>International Classification of Primary Care, 2nd Edition</i>
ICD-9	<i>International Classification of Diseases, 9th Revision</i>
ICD-10	<i>International Classification of Diseases, 10th Revision</i>
MCM	Major congenital malformations
NDD	neurodevelopmental disorders
PASS	Post-authorisation safety study
PPRN	PHARMO perinatal research network
THL	Finnish Institute for Health and Welfare, Finland
STROBE	Strengthening the Reporting of Observational Studies in Epidemiology
UiO	University of Oslo
VAC4EU	Vaccine Monitoring Collaboration for Europe
VID	The Valencia Health System Integrated Database
VHIR	Vall d'Hebron - Institut de Recerca

3 Marketing Authorisation Holder

Not applicable.

4 Responsible Parties

4.1 Investigators

Note: the numbers under roles correspond to the numbers under key persons to clarify the role each person has in this study.

Organisation	Key person	Role(s)
Utrecht University, Division of Pharmacoepidemiology & Clinical Pharmacology, David de Wiedgebouw, Universiteitsweg 99, 3584 CG Utrecht, the Netherlands	1. Prof. Dr. Olaf Klungel 2. Dr. Shahab Abtahi 3. Ms. Elizabeth Comberg 4. Dr. Patrick Souverein 5. Drs. Magdalena Gamba 6. Drs. Svetlana Belitser 7. Dr. Satu Siiskonen 8. Ms. Ana Pelkmans	1. Consortium management 2. Study co-lead 3. Support study co-leads 1-6. Data access provider CPRD 4,5. Programming 6. Statistical support 7. Finances 8. Legal affairs
UMC Utrecht (UMCU) Heidelberglaan 100, 3584 CX Utrecht, the Netherlands	1. Prof. Dr. Miriam Sturkenboom 2. Dr. Carlos E. Durán 3. Drs. Si Han 4. Drs. Judit Riera-Arnau 5. Drs. Vjola Hoxhaj 6. Drs. Odette de Bruin 7. Drs. Nicoletta Luxi	1. Scientific coordination, and principal investigator 2. Study co-lead 3. Support study co-lead 4, 5. Data quality assessment 4, 6. Medical expertise 7. Scientific support (core team of ADEPT)
Agenzia regionale di sanità (ARS) della Toscana Via Pietro Dazzi, 1 - 50141 Florence, Italy	1. Dr. Rosa Gini 2. Dr. Giuseppe Roberto 3. Drs. Davide Messina	1-2. Programming support, expertise in and support with pregnancy algorithm expertise 3. Component analysis
Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain	1. Dr. Maria Giner-Soriano 2. Dr. Rosa Morros 3. Dr. Dan Ouchi	1-3. Data access provider (SIDIAP database). Pharmacoepidemiology expertise
Fundacio Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR), Barcelona, Spain	1. Dr. Monica Sabaté 2. Drs. Judit Riera-Arnau 3. Ms. Elena Ballarín 4. Dr. Antònia Agustí	1-4. Medical expertise
University of Toulouse III, CHU Toulouse, CERPOP, France	1. Dr. Christine Damase-Michel 2. Dr Justine Benevent 3. Dr Anna-Belle Beau	1-3. Data access provider, expertise in conduct of pregnancy studies, pharmacoepidemiologic expertise

Finnish Institute for Health and Welfare (THL), Finland	1. Dr. Maarit Leinonen 2. Mr. Visa Martikainen	1-2. Data access provider, expertise in conduct of pregnancy studies
University of Oslo, Norway	1. Prof. Dr. Hedvig Nordeng 2. Mr. Saeed Hayati 3. Mr. Mahmoud Zidan	1-3. Data access provider, expertise in conduct of pregnancy studies
FISABIO, Health Services Research and Pharmacoepidemiology (HSRP) Unit, Valencia, Spain	1. Dr. Gabriel Sanfelix 2. Dr. Clara Rodriguez 3. Dr. Francisco Sanchez 4. Dr. Isabel Hurtado 5. Dr. Celia Robles 6. Dr. Aníbal García	1-6. Data access provider, expertise in conduct of pregnancy studies, pharmacoepidemiologic expertise. 2. Scientific support (core team of ADEPT)
INSPIRE, Italy	1. Prof. dr. Gianluca Trifirò 2. Dr. Ylenia Ingrassiotta 3. Mr. Marco Villa 4. Dr. Katia Santacà 5. Drs. Nicoletta Luxi	1-3. Data access provider, pharmacoepidemiologic expertise. 4. Component analysis, programming support. 5. Scientific support (core team of ADEPT)
PHARMO Institute, the Netherlands	1. Ms. Anna Marza Florensa 2. Dr. Eline Houben 3. Dr. Josine Kuiper 4. Prof. Dr. Ron Herings	1-4. Data access provider, expertise in conduct of pregnancy studies
University of Manchester, the UK	1. Dr. Rebecca Bromley	1. Expertise in neurodevelopmental outcomes
Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Calle Campezo 1, Edif. 8, 28022, Madrid, Spain	1. Dr. Mar Martín Pérez 2. Dr. Elisa Martín Merino 3. Dr. Ana Llorente García 4. Dr. Patricia García Poza	1-4. Data Access Provider, pharmacoepidemiologic expertise
Vaccine Collaboration for Europe (VAC4EU), Belgium.	1. Drs. Sima Mohammadi	1. Expertise on generating code list of diseases and drugs of interest.
Teamit Institute, Spain	1. Dr. Fabio Riefolo 2. Dr. Anna Bonaterra-Pastra 3. Dr. Elena Palà	1-3. Study manager

5 Abstract

Title: The utilisation of antiseizure medications in pregnant women, and women and men of childbearing age (ADEPT): a multi-database study from 6 European countries.

Background: Currently there is substantial evidence on teratogenicity of several antiseizure medications (ASMs) and a potential increased risk of neurodevelopmental disorders in young children exposed *in utero* to ASMs. Recently, few evidence has emerged expanding this risk also when there was a paternal exposure before conception, and questions remain regarding the feasibility of studying this association in large electronic healthcare databases. On that line, European Medicines Agency (EMA) asked for an updated evaluation on trends in use of various ASMs and related drugs in pregnant women, and in women and men of childbearing age.

Objectives: The main objective of this study is to describe the utilisation of ASMs and related drugs (i.e., antiepileptics (ATC codes N03A), gabapentinoids (N02BF), and all benzodiazepines with antiepileptic properties) in pregnant women, and women (12-55 years of age), and men of childbearing age (12 years and older),. It has the following sub-objectives: 1.1) To estimate the annual incidence and prevalence rate of ASM use in women and men of childbearing age; 1.2) To describe treatment duration, discontinuation, and treatment switches to other ASMs or alternative medications and polytherapy in women and men of childbearing age; 1.3) To estimate pre-pregnancy ASM use, and initiation and continuous use of ASMs during pregnancy period; 1.4) To estimate pre-pregnancy, early and late discontinuation of ASMs, treatment switches to other ASMs or alternative medications and polytherapy among pregnant women; 1.5) To estimate dose changes of ASMs in women prior to and during pregnancy.

Study Design: Retrospective population-based cohort study.

Study Population: The source population comprises over 69.6 million individuals in the included data sources (BIFAP, SIDIAP, VID, CPRD GOLD, Finnish health registries, EFEMERIS, Norwegian health registries, and Val Padana LHU). Persons without information on age and sex, and those without at least one day of observation in the study period (1/1/2000- latest availability) will be excluded.

Exposure and outcomes: The main exposures of interest are ASMs (N03A), including gabapentinoids (N02BF) and benzodiazepines with antiepileptic properties. The drug utilisation outcome measures will be the incidence and prevalence of ASM use among women and men of childbearing age, treatment duration of ASM, discontinuation of ASMs, initiation of ASM and continuous use during pregnancy, switching to another ASM or an alternative medication, dose changes of ASMs before and during pregnancy, and polytherapy of ASMs.

Data Management: The study will be conducted in a distributed manner using the EU PE&PV, ConcePTION, and VAC4EU tools, procedures, and programming pipeline. All partners will extract, transform, and load (ETL) their data instances into the ConcePTION Common Data Model (CDM) tables. To verify the correctness of the ETL process and validity of findings, the INSIGHT level 1 to 2 quality checks will be deployed.

Data Analysis: According to the sub-objectives stated above, statistical estimates will be produced, such as descriptives (counts, percentages), distributions (mean, percentiles), rates (incidence, prevalence), or other relevant measures, using a common R script. Various visualisations (e.g., flow diagrams, line and bar charts) will depict the findings, using SPSS or R.

6 Amendments and Updates

Date	Amendment	Justification	Protocol Section
Jan-Mar 2025	A simple Statistical Analysis Plan (SAP) has been developed in few versions over the winter 2025 to help with the WP1 analyses.	This simple SAP specifies numerators and denominators for the analyses in each sub-objective. Following EMA recommendation, a summary table was added to the study protocol document to improve clarity, transparency, and readability of the planned analyses.	10.8 Data analysis
Apr 2025	Only CPRD Gold will be used in this study, and not Aurum	Only the CPRD Gold data source has the needed information for the father-baby linkage (i.e., the household number, or famnum)	10.2 Study setting
Apr 2025	The approach for capturing drug indications was revised to solely using diagnostic codes. The previous Table 5 (Possible algorithms for indication of drugs, modified from Madley-Dowd et al.) was hence removed, and details described in the main text.	To simplify and harmonise indication definitions, avoid the conflict with the exposure definitions (ASM use) across data sources, and improve methodological consistency.	10.4.3.2 Indications for ASM exposure
May-Jun 2025	Addition of Table 7. Sub-group classification of ASMs, providing the classification of individual ASMs into predefined therapeutic subgroups used in the analyses.	To improve transparency and consistency of subgroup-level analyses. The classification was developed based on a literature review, considering ASM market entry year and previously published classifications (e.g., first-, second-, and third-generation ASMs; conventional and newer-generation ASMs).	10.8 Data analysis
May-Aug 2025	The methodology for estimating treatment duration, and constructing treatment episodes was revised to incorporate specifications of the 8 heterogeneous data sources included in ADEPT. Table 5 was also added.	The amendment improves feasibility and harmonisation across heterogeneous EHR or claims/administrative data sources with differing medication information availability.	10.4.1.3 Operational definitions of exposure
Jul-Sep 2025	The methodology for calculating ASM daily dose was revised, based on the updated information on treatment duration (see above), with tailored approaches for the 8 EHR and claims/administrative data sources in ADEPT. The focus of this analysis was specifically on pregnant women using ASMs around pregnancy.	The amendment improves the accuracy and feasibility of dose estimation across heterogeneous data sources and better aligns with the prescription or dispensing information available in the participating data sources.	10.4.1.3 Operational definitions of exposure 10.8 Data analysis
Sep 2025-Feb 2026	The list of collaborators was revised.	As people joined an organisation or quit jobs during the life span of the project.	4. Responsible parties
Oct 2025	PHARMO withdrew from contributing to ADEPT Objective 1 (this current study).	PHARMO was unable to deliver Objective 1 within the planned timelines due to technical,	10.2 Study setting

		methodological, and organisational challenges. These included issues affecting the quality of linkage between PHARMO out-patient pharmacy data and Perinatal Registry data, particularly mother–child linkage, which would compromise the quality and accuracy of analyses, and difficulties applying the common data model across partially overlapping datasets with varying follow-up periods.	
Oct 2025-Nov 2025	Revision in the analysis plan respecting the stratified analysis in several sub-objectives, including addition of stratification by indication for initiation and continuous use of ASMs in pregnancy (sub-obj 1.3), removal of stratification by indication and comorbidities for discontinuation and switching rates (sub-obj 1.2), and removal of stratification by indication for discontinuation and switching rates in pregnancy (sub-obj 1.4).	To add clinical meaning to the stratified analysis of outcome measures during pregnancy; the amendment also simplifies the analytical framework, based on the feasibility of conducting stratified analysis, especially when there were some low counts in such outcome measures, as discussed with EMA.	10.8 Data analysis
Oct 2025-Nov 2025	A sensitivity analysis of ASM polytherapy was introduced, using a 120-day overlap definition, instead of a 6-months overlap.	As suggested by EMA, and to capture other situations of a polytherapy of ASMs in men and women of childbearing age.	10.8 Data analysis
Oct 2025- Mar 2026	The study title has been revised.	After PHARMO withdrew from this study (so the number of included countries changed), and also based on comments received from the consortium and EMA.	1. Title

7 Milestones

Table 1. Milestones for the various stages of conduct of the study.

Contract signature	18/04/2024
Start of the project	16/05/2024
Start of data collection	15/11/2024*
End of data collection	28/02/2025
Study protocol	16/09/2024
Study report	16/09/2025

*This is 2022 for EFEMERIS, as they reuse a previously ETL-ed and quality checked data cut for this study.

8 Rationale and Background

Valproates and older antiepileptic drugs

Antiseizure medications (ASMs) are frequently used for a range of indications from epilepsy to bipolar disorders and prophylaxis of migraine attacks. The use of several older ASMs by women during pregnancy has been associated with major congenital anomalies (MCA) and neurodevelopmental disorders (NDD) in the newborn.¹⁻⁴ These medications cause harm to the developing brain leading to poorer neurodevelopmental outcomes in childhood. Because of the increased risk of poorer neurodevelopmental outcomes in children with older ASMs (valproate, phenobarbital), the use of newer ASMs throughout pregnancy has increased. Due to this risk, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has already issued several risk minimisation measures (RMMs) to contain the use of valproate and topiramate in women of childbearing potential and pregnant women.^{5,6} Awareness about these risks has increased and led to better evidence-based prescribing and preconceptual counselling regarding older ASMs for women of childbearing potential with epilepsy.⁷

Several studies investigated on the impact of 2014 and 2018 RMMs on valproate utilisation in Europe, where most reported a decline in valproate use and concurrent pregnancies with valproate exposure especially after the 2018 RMMs.⁸⁻¹³ Two recent studies conducted for EMA showed a general decline in use of valproate in Europe in women of childbearing potential between 2010 and 2020,⁸ and 2021.⁹ There was between 3.3% (in the Netherlands) and 11.3% (in Spain) reduction in prevalent use of valproates in the studied countries/regions after the 2018 RMMs compared to the period before. However, a substantial number of concurrent pregnancies were still happening in the studied databases (ranging between 0.34-1.13 concurrent pregnancies per 1000 valproate user before the 2018 RMMs to 0.00-5.07 in the period after).⁸

Also, a study from PHARMO in the Netherlands reported a reduction in use of valproate in women of childbearing potential between 1998 and 2019 (-15%), but an increased use of other teratogenic ASMs, topiramate (+13%) and lamotrigine (+8%).¹⁴ A multi-centre study showed that overall ASM use in 3-months before pregnancy continued to rise in Nordic countries, Australia and USA between 2006 and 2012 (or 2016 depending on data availability).¹⁵ While valproate use showed a declining trend in almost all centres, use of lamotrigine and topiramate rose substantially. In the UK, despite reductions in sodium valproate prescriptions, the prevalence of ASM prescribing during pregnancy in the general population rose from around 6 to 12 per 1000 pregnancies between 2007 and 2016, largely due to increases in prescriptions of pregabalin, gabapentin and lamotrigine.¹⁶ Discontinuation of ASMs before or during pregnancy is common (19%–38% of women prescribed any ASM before pregnancy are not prescribed during pregnancy and the prevalence of prescription declines between the first and later trimesters of pregnancy),¹⁵ but the discontinuation was clearly less common when ASM was prescribed for epilepsy.¹⁷

Newer (other) antiepileptic drugs

Valproate is the most teratogenic ASM, but also other ASMs have been associated with an increased risk of MCA. Comparatively, conclusions regarding exposure to newer ASMs and the potential negative impact on later child development remain limited. In a Cochrane review of 28 studies a paucity of research into lamotrigine, levetiracetam, and topiramate was highlighted, with no data available for oxcarbazepine, perampanel, eslicarbazepine, or zonisamide.^{2,18} Although the study of newer ASMs has since increased, findings are mixed, and methodologies used to investigate child neurodevelopment following in utero exposure vary widely.¹⁸ A recent multicentre study from Nordic countries, USA and Australia showed that lamotrigine-levetiracetam duo-therapy in first trimester was associated with a 59% lower risk of MCA than valproate monotherapy, while lamotrigine-topiramate was not associated with a reduced risk.¹⁹ Recent concerns about the possible impact of levetiracetam monotherapy and duo-therapy exposures have been raised.^{20,21} However, only few studies have the remit to assess short- and long-term outcomes, both of which are crucial to understanding the impact of ASMs on the trajectory of brain development from infancy to early adulthood.²²

Paternal exposure to ASMs

In addition to the teratogenicity risk with maternal use of ASMs, a recent observational study from Denmark, Norway and Sweden suggests a 50% higher risk (pooled estimate) of NDD in children of men who were using valproate in 3-months before conception compared with men who used other ASMs such as lamotrigine/levetiracetam.²³ Based on this study, PRAC recommended precautionary measures, such as considering effective contraception for male patients who use valproates and close supervision by a specialist.²⁴ Also very recently, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) recommended a set of RMMs for male patients using valproate.²⁵ However, these positions from EMA and MHRA were criticised later and deemed without enough substantiation from underlying scientific evidence.²⁶ Additionally, there was another recent study from Denmark that failed to show such an association between paternal valproate exposure and offspring risk of MCA or NDD.²⁷ Hence, this possible link deserves further investigation.

Need for further information

Considering the current evidence on teratogenicity of several ASMs and a potential increased risk of NDD in young children not only exposed in utero to ASMs but also when there was a paternal exposure before conception, EMA requires an updated evaluation on trends in use of various ASMs and related drugs (ATC codes N03A and N02BF) in both women and men of childbearing age in Europe. It is also deemed necessary to assess whether causal inference studies on ASMs and MCA or NDD will be feasible, particularly given that father-child linkage is a more challenging and less explored area than mother-child linkage when using real-world data.

9 Research Question and Objectives

The main objective of this study is to describe the utilisation of ASMs and related drugs (ATC codes N03A and N02BF) in pregnant women, and women and men of childbearing age, using data from 8 electronic healthcare databases from two Nordic (Finland, Norway), one western (the UK), and three southern European countries (France, Italy, Spain).

The main objective will be met with the following sub-objectives:

Sub-objective 1.1 To estimate the annual incidence and prevalence rate of ASM use in women (12-55 years of age) and men of childbearing age (12 years and older) overall and by age group, indication, data source and calendar year (population base cohort).

Sub-objective 1.2 To describe treatment duration, discontinuation, and treatment switches to other ASMs or alternative medications and polytherapy in women (12-55 years of age) and men of childbearing age (12 years and older) who receive a new ASM prescription/dispensing in a specific calendar year, by data source, age, indication, calendar year and ASM (ASM user cohort).

Sub-objective 1.3 To estimate pre-pregnancy ASM use, and initiation and continuous use of ASMs during the pregnancy period, by data source, age, and indication in all pregnant women.

Sub-objective 1.4 To estimate pre-pregnancy, early and late discontinuation of ASMs, treatment switches to other ASMs or alternative medications and polytherapy among pregnant women, by data source, and indication of the ASM.

Sub-objective 1.5 To estimate dose changes of ASMs in women prior to and during pregnancy, by data source.

10 Research Methods

10.1 Study design

This is a retrospective population-based cohort study to describe the utilisation patterns of ASMs in different population cohorts.

10.2 Study setting

This study will be conducted using electronic health record data from 8 data sources in 6 countries in Europe comprising a total population of over 69.6 million persons. Main characteristics of the participating data partners and access providers are presented in Table 2. The source population comprises all women (12-55 years old) and men of childbearing age (≥ 12 years old). Data sources vary in the type of data banks that can be accessed. Some DAPs will re-use the data instance they use for ConcePTION (UiO, CHUT), whereas other DAPs will re-extract and use the requested ad-hoc populations (THL, AEMPS, IDIAPJGol, FISABIO, UU, INSPIRE).

Table 2: Overview of data sources.

DEAP	Data source and country	Active Population size (mil)	Data provenances available for this study (Record linkage)	Vocabularies	Data update frequency	Years with complete data
AEMPS	BIFAP (ES)	24.0	Primary care records and hospital discharge diagnosis.	ICPC2/SNOMED ICD9CM, ICD10CM, ATC	6 months	2005- 2024
VHIR/IDI APJGol	SIDIAP (ES, Catalonia)	6.0	Primary care records, specialist referrals, ICU admission, hospital discharge diagnosis, pregnancy register, child health records, pharmacy dispensing.	ICD10CM, ATC, ICD10-PCS	6 months	2010-June 2024
FISABIO	VID (ES, Valencia region)	5.0	Primary care records, outpatient specialist records, lab tests, emergency room visits, hospital admissions and procedures, ICU admission, pregnancy register, child health records, outpatient pharmacy prescribing and dispensing. Several associated registries or information systems such as perinatal mortality register, congenital anomalies register, vaccines information system, etc.	ICD10CM & ICD9CM, ATC	Yearly	2009-2024
UU	CPRD-GOLD (UK)	21.6	Primary care diagnoses, prescriptions, lab tests, hospital admissions and procedures (HES APC, A&E, OP), pregnancy data, living situation, child health records.	Read codes(BNF), ICD10CM OPCS	Few months for HES and pregnancy	1987-2024
THL	Finnish health registries (FHR, FI)	5.5 (1.7 pregnancies)	Available instance restricted to pregnant women who gave birth or terminated pregnancy and their children. Primary care record, ICU,	ICD10CM, ATC, ICPC-2, NOMESCO	Depending on data source, from 1 month to 1 year.	1996-2022

			emergency room, hospital discharge diagnosis, pregnancy registry, congenital anomaly register, outpatient pharmacy dispensing.			
CHUT*	EFEMERIS (FR)	1.4 (0.18 pregnancies)	Available instance restricted to pregnant women who gave birth or terminated pregnancy and their children. Hospital discharge diagnosis, outpatient pharmacy dispensing, and child health records, no ICU, no primary care.	ICD10CM, ATC	Yearly	2005-2021
UHO	Norwegian health registries (NO)	5.3 (2.1 mother or father/children)	Primary care records (KUHR), outpatient specialist diagnosis (KUHR/NPR), emergency room visits (KUHR), hospital discharge diagnosis (NPR), outpatient pharmacy dispensing (NorPD).	ICD10, ICPC, ATC	Yearly†	2008-2021
INSPIRE	Val Padana LHU (IT)	0.78	Hospital discharge diagnosis, pharmacy records, ICU admission, emergency room, outpatient specialists, congenital anomalies, birth registry.	iCD9CM, ATC, Italian code system for exemptions	yearly	2009-2024

* Pregnancies only

† The 2008-2021 data set will be used, no updates in this project.

10.3 Source and study population

The source population comprises all persons in the data sources that will participate in this study. From the source population, we will select various cohorts that feed data for the different sub-objectives in this study (Figure 1). Persons will be included in the study population when they have:

- Information on age and sex available.
- Have at least one day of observation in the study period (1/1/2000- latest availability).

Follow-up will start and end based on in-and exclusion criteria which differ per sub-objective.

10.3.1 Base cohort

This base cohort provides data used in denominators of rates in sub-objective 1.1. The eligibility criteria for the base cohort are shown in Figure 1.

Follow-up will start at the latest date of the following criteria:

- Reaching 12 years of age.
- One year of available data (run-in period) in the data source.

Follow-up will end at the earliest of any of the following criteria:

- Reaching age 56 years for women only (there is no upper age limit for men)
- Death
- Moving out of the data source (disenrollment)
- Last data available from the data source (or parts of it)
- Last data extraction for relevant data sources.




Figure 1. Establishment of various study cohorts used to feed objectives of ADEPT.
ASM: Antiseizure medication.

10.3.2 ASM (new) user cohort

This cohort provides data for numerators of rates in sub-objective 1.1, and the rest of outcome measures in sub-objective 1.2. The (new) ASM user cohort will be a sub-cohort from the base cohort and comprises individuals therefrom who receive at least one ASM prescription/dispensing (Figure 2). These individuals may be either new or prevalent ASM users. New (incident) ASM users will be defined as no ASM use in the 1-year look-back period (i.e., 365 days prior to the prescription/dispensing date of an ASM). While prevalent ASM users will be those individuals with ASM use in the 1-year look-back period. All ASM users will be followed from the start of the 1st ASM prescription/dispensing, until the end of follow-up as defined under the base cohort 10.3.1.




Figure 2. Study designs for the base cohort, and ASM (new) user cohort.

10.3.3 Pregnancy cohort regardless of ASM

From the base cohort defined in objective 1.1, we will create a sub-cohort of pregnancies. One individual may have multiple pregnancy episodes. The start of pregnancy will be defined as the estimated first day of the last menstrual period (LMP); end of pregnancy will be the date of delivery or abortion (elective/spontaneous). Pregnancy start and end dates will be assessed based on the data banks used to detect the pregnancy periods using the ConcePTION pregnancy algorithm <https://github.com/ARS-toscana/ConcePTIONAlgorithmPregnancies>. The algorithm allows the identification of pregnancies from 4 streams of information:

- Stream PROMPTS: uses data source specific information (e.g. LMP, end of pregnancy) from birth registries, terminations registries, and spontaneous abortion registries: the existence of one of such record implies readily that a pregnancy has ended.
- Stream EUROCAT: records of the EUROCAT table in the CDM. Some data sources include a data bank that is compliant with the standard of EUROCAT, the European network of population-based registries for the epidemiological surveillance of congenital anomalies (https://eu-rd-platform.jrc.ec.europa.eu/eurocat_en). Such records are copied with minimal conversion to a special table of the ConcePTION CDM, named EUROCAT. “Stream EUROCAT”: are the records retrieved from the EUROCAT table when the pregnancy algorithm of ConcePTION is applied.
- Stream CONCEPTSETS: this stream uses a large list of diagnostic codes from the events or procedure codes referring to a start, end or an ongoing pregnancy.

- Stream ITEMSETS: variables from ordinary healthcare that are only populated when a woman is pregnant. Some data sources include data banks that contain surveillance data, for example birth registries, or results from diagnostic tests. In such data, information is labelled as a ‘data item’.²⁸ For example an item is the question ‘what is the gestational age at the visit date?’ and the answer may be a number (in weeks, or in days, or in months), or a categorical variable (‘at term’, ‘preterm’, ...). An ‘itemset’ is a set of records retrieved from the data source that have such complex structure. The Stream ITEMSET is the set of itemset records that are retrieved from the data source with the purpose of identifying a pregnancy and its characteristics

The resulting sets of pregnancies of the same person are then compared with each other, to identify which pregnancies are in fact the same recorded on multiple occasions. The algorithm first identifies pregnancies from any possible records and subsequently establishes the start and end date of pregnancy by processing all the available information in a hierarchical manner. Hierarchy is based on how the identification of the start and end dates of the pregnancy was performed.

The output of the ConcePTION Pregnancy algorithm is the start and end date of pregnancy, or ongoing pregnancies. Pregnancies will be included in the cohort of pregnancies when the following criteria apply:

- Start date of pregnancy is during follow-up period as defined under objective 1.1.
- One year of available data (run-in period) in the data source at the start date of the pregnancy (LMP). For EFEMERIS this is 2.5 months and for THL 3 months.

Follow-up will end at the end date of the pregnancy, or the end of follow-up (as specified in 10.3.1. Base cohort), whichever is earliest. This includes ongoing pregnancies.

10.3.4 ASM user pregnancy cohort

This cohort will be used to address sub-objectives 1.3, 1.4 and 1.5. Here, we will use the pregnancy cohort regardless of ASM (see above) with additional inclusion criteria of:

- A prescription/dispensing for ASM in the 12 months (3 months for THL and 2.5 months for EFEMERIS) prior to pregnancy start date, or
- A prescription/dispensing for ASM during pregnancy.
- Availability of information on prescribed daily dose in the data sources (only for sub-objective 1.5).

Start of follow-up (t=0) in this cohort will be the ASM prescription/dispensing date. Pregnancies without ASM in the year prior or during pregnancy will be excluded.

Follow-up will end at the end date of the pregnancy, or the end of follow-up (as specified in 10.3.1. Base cohort), using the same principles as depicted in Figure 2.

10.4 Variables

10.4.1 Exposure

10.4.1.1 Antiseizure medications (ASMs)

The main exposures of interest are ASMs (N03A), gabapentinoids (N02BF) and benzodiazepines with antiepileptic properties. Table 3 shows the ATC codes and the defined daily doses (DDDs) for all products listed in these classes. Some may not be used anymore or are not yet approved, but this will be observed in the study. We included gabapentinoids (N02BF) because they were widely used for similar indications as other ASMs and were classified as ‘Other antiepileptics’ under N03AX by the WHO Collaborating Centre for Drug Statistics Methodology until March 2022.

All ASM records will be extracted, transformed, and loaded (ETL) from the local data source drug nomenclature to ATC codes or available ATC or BNF codes into the MEDICINES and PRODUCTS table of the ConcePTION CDM v2.2. The PRODUCTS table will comprise information on the strength of the drugs.

Table 3. Exposure of interest, with ATC codes and defined daily dose values as per WHO/ATC system.

ATC code	Name of ASM	DDD value	DD unit	Route of administration	Indication
N03AA01	methylphenobarbital	0.5	g	O	Relief of anxiety, tension, and apprehension, anticonvulsant*
N03AA02	phenobarbital	0.1	g	O, P	All types of seizures (except absence seizures), sedation*
N03AA03	primidone	1.25	g	O	Management of grand mal, psychomotor, and focal epileptic seizures, essential tremor*
N03AA04	barbexaclone				Epilepsy*
N03AA30	metharbital	0.2	g	O	Epilepsy†
N03AB01	ethotoin	2.5	g	O	Control of generalised tonic-clonic (grand mal) and complex-partial (psychomotor) seizures*
N03AB02 N03AB52	phenytoin	0.3	g	O, P	Focal and generalised onset seizures, status epilepticus*
N03AB03	amino(diphenylhydantoin) valeric acid	0.3	g	O	n/a
N03AB04 N03AB54	mephenytoin	0.4	g	O	Refractory partial epilepsy†
N03AB05	fosphenytoin	0.45	g	P	Various seizures (generalised tonic-clonic status epilepticus and prophylaxis during craniotomy)*
N03AC01	paramethadione	0.9	g	O	Refractory absence (petit mal) seizures†
N03AC02	trimethadione	1.5	g	O	Refractory absence (petit mal) seizures†
N03AC03	ethadione				n/a
N03AD02	phensuximide	2	g	O	Absence (petit mal) seizures†
N03AD03	mesuximide	0.9	g	O	Refractory absence (petit mal) seizures*
N03AD01 N03AD51	ethosuximide	1.25	g	O	Absence (petit mal) seizures*
N03AE01	clonazepam	8	mg	P, O	Panic disorder, refractory seizures, seizure disorders (Lennox-Gastaut syndrome, akinetic, myoclonic seizures, and absence seizures), REM sleep behavioral disorders*,‡
N03AF01	carbamazepine	1	g	O, R	Bipolar disorder, focal (partial) and generalised onset seizures (except absence seizures), neuropathic pain*
N03AF02	oxcarbazepine	1	g	O	Focal (partial) onset seizure*
N03AF03	rufinamide	1.4	g	O	Lennox-Gastaut syndrome*
N03AG01	valproic acid	1.5	g	O, P, R	Bipolar disorder, focal (partial) and generalised onset seizures, prevention of migraine attacks*
N03AG02	valpromide	1.5	g	O	Bipolar disorder, depression, epilepsy, psychomotor agitation†
N03AG03	aminobutyric acid	1	g	O, P	Epilepsy‡
N03AG04	vigabatrin	2	g	O	Infantile spasms, refractory complex partial seizures*
N03AG05	progabide				Epilepsy†
N03AX03	sultiame	0.4	g	O	Focal epilepsy†
N03AX07	phenacemide	1.5	g	O	Epilepsy†

N03AX09	lamotrigine	0.3	g	O	Bipolar disorder, focal (partial) and generalised onset seizures*
N03AX10	felbamate	2.4	g	O	Focal (partial) onset seizures, Lennox-Gastaut syndrome*
N03AX11	topiramate	0.3	g	O	Prevention of migraine attacks, various seizures*
N03AX13	pheneturide				Seizures*
N03AX14	levetiracetam	1.5	g	O, P	Focal (partial) and generalised onset seizures*
N03AX15	zonisamide	0.2	g	O	Focal (partial) onset seizures*
N03AX17	stiripentol	1	g	O	Dravet syndrome-associated seizures*
N03AX18	lacosamide	0.3	g	O, P	Focal (partial) onset seizures, primary generalised tonic-clonic seizures*
N03AX19	carisbamate				Adjunctive treatment of partial onset seizures with or without secondary generalisation [†] <i>Withdrawn application to EMA</i>
N03AX21	retigabine	0.9	g	O	Partial-onset seizures*
N03AX22	perampanel	8	mg	O	Partial-onset seizures, primary generalised tonic-clonic seizures*
N03AX23	brivaracetam	0.1	g	O, P	Partial-onset seizures*
N03AX25	cenobamate	0.2	g	O	Adjunctive treatment of focal-onset seizures with or without secondary generalisation [†]
N03AX26	fenfluramine	8	mg	O	Seizures associated with Dravet syndrome and Lennox-Gastaut syndrome [‡]
N03AX27	ganaxolone	n/a	n/a	n/a	Epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) [§]
N03AX30	beclamide	n/a	n/a	n/a	Epilepsy and epilepsy related behavioural disorders [†]
N02BF01 (& N03AX12)	gabapentin	1.8	g	O	Epilepsy, neuropathic pain [#]
N02BF02 (& N03AX16)	pregabalin	0.3	g	O	Epilepsy, neuropathic pain, generalised anxiety disorder [†]
N02BF03	mirogabalin	25	mg	O	Peripheral neuropathic pain [†]
N03AF04	eslicarbazepine	0.8	g	O	Focal onset seizures, Seizures, partial onset*
N05BA01	diazepam	10	mg	O, P, R	first-line treatment of status epilepticus [‡]
N05BA06	lorazepam	2.5	mg	O, P, SL	first-line treatment of status epilepticus [‡]
N05BA09	clobazam	20	mg	O	adjunctive treatment for Lennox-Gastaut syndrome; difficult-to-treat seizures, drop seizures [‡]
N05CD08	midazolam	5, 15, 10	mg	N, O, P, SL	first-line treatment for status epilepticus (off-label) [‡]
* Uptodate.com/Lexicomp [†] DrugBank (www.go.drugbank.com) [‡] Brigo F, Lattanzi S. Anti-convulsant Agents: Benzodiazepines (Clobazam, Clonazepam, Diazepam, Lorazepam, Midazolam). <i>NeuroPsychopharmacotherap</i>. 2022. Springer.²⁹ [§] Bryson A, Reid C, Petrou S. Fundamental neurochemistry review: GABA_A receptor neurotransmission and epilepsy: principles, disease mechanisms and pharmacotherapy. <i>Journal of neurochemistry</i>. 2023 Apr;165(1):6-28.³⁰ [#] European Public Assessment Report (www.ema.europa.eu/en/glossary/european-public-assessment-report) [†] CIMA, AEMPS (https://cima.aemps.es/cima/publico/home.html) [‡] Deeks ED. Mirogabalin: first global approval. <i>Drugs</i>. 2019 Mar 1;79(4):463-8.³¹ Abbreviation: n/a: not available.					

10.4.1.2 Alternative medications of ASMs

In sub-objectives 1.2 and 1.4, we will explore switching trends from ASM to alternative medications based on the different indications listed in Table 4. The list of alternative medications that will be retrieved are presented in Table 4. Noteworthy, not all products are available in all data sources.

Table 4. List of alternative medications for ASMs per indication area of the ASM.

<i>Indication</i>	<i>Alternative medications of ASMs</i>
Epilepsy (drug resistant)	Cannabidiol
Bipolar diseases	Lithium, quetiapine, olanzapine, aripiprazole, risperidone, asenapine, lurasidone, or paliperidone.
Prevention of migraine attacks	Beta-blockers (Metoprolol, propranolol, timolol, atenolol and nadolol), calcium channel blockers (nifedipine, verapamil, nimodipine, and flunarizine), ACE inhibitors/ARBs (lisinopril and candesartan), antidepressants (amitriptyline and venlafaxine), CGRP antagonists (erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, atogepant), NSAIDs (naproxen), pizotifen.
Generalised anxiety disorder	SSRIs (paroxetine, sertraline, citalopram, escitalopram, fluoxetine and fluvoxamine), SNRIs (venlafaxine, and duloxetine); benzodiazepine (e.g., lorazepam), hydroxyzine, buspirone, mirtazapine
Neuropathic pain (or nociceptive, centralized pain, or fibromyalgia)	TCAs (amitriptyline, doxepin, imipramine, nortriptyline, desipramine, maprotiline), SNRIs (venlafaxine, duloxetine, milnacipran), topical therapy (e.g., topical NSAIDs, topical lidocaine, or capsaicin patch), opioids and botulinic acid,
Restless legs syndrome	Iron supplementation, carbidopa-levodopa, benzodiazepines (clonazepam, and zolpidem)
Essential tremor	Beta-blockers (propranolol, sotalol, nadolol, atenolol, metoprolol); benzodiazepines (alprazolam and clonazepam)
Major Depression	SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), SNRIs (desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine), TCAs (amitriptyline, clomipramine, doxepin, imipramine, trimipramine, desipramine, nortriptyline, protriptyline, maprotiline), atypical antidepressants (bupropion and mirtazapine), serotonin modulators (nefazodone, trazodone, vilazodone, vortioxetine), MAOIs (isocarboxazid, moclobemide, phenelzine, selegiline, and tranylcypromine).
Schizophrenia (psychosis)	first- and second-generation long-acting injectable antipsychotics (fluphenazine, haloperidol, paliperidone, aripiprazole, olanzapine, risperidone)
* Uptodate.com/Lexicomp Abbreviation: CGRP: Calcitonin gene-related peptide, ACE: angiotensin-converting enzyme, ARBs: angiotensin receptor blockers, TCAs: tricyclic antidepressants, SSRIs: Selective serotonin reuptake inhibitors, SNRIs: serotonin-norepinephrine reuptake inhibitors, MAOI: Monoamine oxidase inhibitors, NSAIDs: non-steroidal anti-inflammatory drugs.	

10.4.1.3 Operational definitions of exposure

Estimating ASM treatment duration and constructing exposure episodes

To estimate the treatment duration and the proportion of discontinuers and switchers, we will construct treatment episodes. Treatment episodes are defined as the treatment periods from index prescription/dispensing to the expected end date of a continued last prescription/dispensing, including a grace period of 30 days between prescription/dispensing of the same ATC code (see Figure 3-A).

First, we will calculate the duration of prescriptions/dispensings. Given the heterogeneity of data availability across participating databases, different approaches will be applied depending on the information available in each data source. A tailored strategy will be adopted, varied in general in the electronic health record (EHR) databases than in the claims/ administrative ones. In the EHR databases, the general approach will be to use the direct information on a prescription length from doctor/ nurse, the number of tablets (and/or the number of packages), the prescribed/dispensed dosing regimen, and when this information is not available, using a fixed duration of use (see Table 5). In claims/administrative databases, the general approach will be using the total number of DDDs

dispensed, assuming a regimen of 1 DDD per day, and then a fixed duration of use when this information is not available. This information will be fed then the previously validated AdhereR function to generate the treatment episodes ³².

Table 5. Strategies used to estimate the treatment duration of a prescription/ dispensation record in each data source in ADEPT.

<i>Data source</i>	<i>Strategy used</i>
CPRD	The local algorithm used, as below: 1. An estimated treatment length calculated as total number of tablets divided by the daily prescribed regimen (capping rules and replacement apply for implausible and missing values); 2. If above information was not available, use direct information recorded on prescription length (capping rules apply for implausible values); 3. If none of the above was available, use a fixed duration of 30 days.
BIFAP	The local algorithm used, as below: 1. When both a written duration (issued by the prescriber) and sufficient data for a calculated duration* are available, the shorter of the two values is selected. For example: If the prescriber indicates a duration of 35 days, but the dispensed quantity is 30 tablets with a posology of 3 tablets/day, the calculated duration is 10 days, which is then assigned as the final duration. *The calculated duration is obtained by dividing the number of prescribed/dispensed units by the number of units to be taken per day (i.e., posology). 2. If only one duration is available, either written or calculated, that value is used. 3. If no duration is available, the time interval between consecutive prescriptions/dispensings is used, provided that this interval falls within the predefined range of acceptable duration values for the medicinal product. 4. If none of the above criteria can be applied, the duration is estimated using the number of Defined Daily Doses (DDD) at the active ingredient level. 5. If no other method is applicable, a default duration of 28 days is imputed.
FISABIO	The local algorithm used, as below: 1. Direct information recorded on prescription length by the doctor 2. If the above information was missing, the duration was imputed sequentially using the mode of the duration by a) person_id and medicinal_product_id, b) medicinal_product_id, and c) active ingredient.
SIDIAP	The local algorithm used, as below: 1. The duration of the prescription is calculated as the difference between the end date of the prescription and the start date plus one. 2. In their system, there are no missing values in this variable, as the start and end dates for a prescription are both mandatory. The start date is usually the date when the prescription was issued, and the end date is manually set by the prescriber. For chronic medications, the system automatically sets a duration of 365 days. 3. Fixed duration of 30 days in case an end date is missing (mostly hypothetical)
Finnish health registries	1. Dispensed number of packages multiplied by total number of DDDs dispensed in 1 package, assuming a regimen of 1 DDD per day; 2. Fixed duration of 90 days for all ASMs, aside from benzodiazepines (N05) with 30 days.
Norwegian health registries	1. Total number of DDDs dispensed in the record, assuming a regimen of 1 DDD per day; 2. Fixed duration of 90 days for all ASMs, aside from benzodiazepines (N05) with 30 days.
EFEMERIS	1. Fixed duration of 30 days.
Val Padana LHU	1. Total number of DDDs dispensed in the record, assuming a regimen of 1 DDD per day; 2. Fixed duration of 30 days.

Calculating daily dose of ASM exposure

The dose investigation will be only conducted in pregnant women who were using ASMs around pregnancy. The strategy for calculating the mean daily dose of ASMs will be also tailored according to the two main types of data sources in ADEPT, i.e., EHR and claims/administrative databases, on top of the work done for estimating the treatment duration (see above). In the EHR databases, the amount of drug used in each prescription will be calculated using the number of tablets (sometimes together with the number of packages) prescribed in each record, and the strength information of the medicinal product (from local medicinal products dictionary files). Then, considering the estimated treatment

duration of the prescription record, and the overlap with the fixed 3-months' time windows before and after pregnancy, the mean weighted daily dose of ASM in that time window will be calculated. If there are several prescriptions of the same ASM in a time window, the total amount used will be calculated by summing the individual amounts from each record. In claims/ administrative databases, the total number of DDDs dispensed in each record, and the overlap between the estimated treatment duration and fixed 3-months' time windows will be used to calculate the mean daily dose of ASMs before and after pregnancy. Similarly, if there are multiple records, we will sum the number of DDDs to have the total amount used. We will classify each exposure as low, mid, and high dose based on DDD equivalents: <0.5 DDD as low, 0.5-1.49 DDD as mid and >1.5 DDD as high. Previous research has shown that daily dose of ASMs in DDDs from prescription fills has a high correlation with blood levels of the used drugs during pregnancy.³³ This cannot be done for data sources without information on dispensed/prescribed dosing regimen.

10.4.2 Drug utilisation outcomes

The drug utilisation outcome measures that will be covered in this study protocol are the incidence and the prevalence of ASM use among women and men of childbearing age, treatment duration, discontinuation of ASMs, switching to another ASM or an alternative medication, and polytherapy of ASMs. Among pregnant women, the drug utilisation outcome measures will be pre-pregnancy use of ASMs, initiation and continuous use of ASMs during pregnancy, discontinuation, switching to other ASMs or alternative medicine during pregnancy, polytherapy, and dose analysis of ASMs before and after pregnancy.

10.4.2.1 Operational definitions of outcomes

Incidence & prevalence of ASM use

Incident use of ASM is defined as a prescription of an ASM without any ASM use in the look-back period (365-days before). Prevalence of ASM is defined as the users (either existing or starting) in a defined period (period prevalence), which will be on a yearly basis for the base population. **Treatment duration of ASMs**

Treatment duration is defined as the number of days of the treatment episode of an ASM from the start until discontinuation or end of follow-up, including the collapsed grace periods (permissible gaps of ≤ 30 days) in between treatment episodes.

Discontinuation of ASMs

In general, we will assume an individual has discontinued the specific drug of interest if no new prescription/dispensing for that drug is identified within 120 days of the last treatment episode (see Figure 3-B). A gap of >30 and <120 days between two treatment episodes will be considered as a 'temporary break' in treatment and no discontinuation. If the distance between end of follow-up and end of treatment episode is less than 120 days, we will not consider the person to have discontinued.

Switching to another ASM

Switching from an ASM to another ASM will be defined when there is an occurrence of a prescription/dispensing of another ASM (different ATC code) during the last treatment episode of the ASM or within the discontinuation period of the ASM (0 to 120 days after the episode end date) (see Figure 3-C). If a record for ASM occurs in the same treatment episode as the new ASM, and the conditions for discontinuation and switch are not met, this will be assessed for classification as polytherapy (see below, Figure 3-D). Switching to alternative medication is defined as an occurrence of a prescription/dispensing of another medication (see 10.4.1.2 & Table 4) during the last treatment episode of the ASM or within the discontinuation period of the ASM.

Polytherapy

Among women and men of childbearing potential, polytherapy is defined as having prescriptions/dispensings filled of two or more different ASMs in a single treatment episode for at least 6 months (i.e., 182 days), where the conditions of a switch (see above) are not met (Figure 3-D).³⁵ The prerequisite of concomitant use of two medications for at least 6 months (i.e., 182 days) is set to exclude practical situations of a switch, where the first medication needed to be tapered and the new one titrated up slowly, which might take a few months.




Figure 3. Handling of treatment gaps, treatment discontinuation, treatment switch, and polytherapy (adapted from Durán CE et al.).³⁴ The various colour boxes represent different antiseizure medications that are prescribed for a hypothetical patient.

Definitions during pregnancy

Within pregnancy, we will classify continuation/discontinuation patterns of ASMs before and during pregnancy inspired from Madley-Dowd et al,³⁶ but based on treatment episodes that will be constructed using the estimated treatment durations and AdhereR functions (see above), with the following categories:

- **Pre-pregnancy ASM use** is defined as a treatment episode of an ASM in the year before pregnancy, which falls within both 12 to 6 months before pregnancy and 6 to 0 months before pregnancy to exclude inconsistent or temporary users.
- **Initiators of ASMs during pregnancy** are those with an ASM treatment episode starting during any trimester, but no such ASM use (treatment episode) in the 12 months prior to pregnancy start. **Continuous ASM use during pregnancy** is defined as pre-pregnancy ASM use (see above) that runs into the first, and second and third trimester.

- **Pre-pregnancy discontinuation** is defined as pre-pregnancy ASM use (see above) that does not run into the pregnancy period.
- **Early discontinuation** is defined as pre-pregnancy ASM use (see above) that runs into the first-trimester but not into the second trimester.
- **Late discontinuation** is defined as pre-pregnancy ASM use (see above) that continues in the first and second trimesters, but ends before the third trimester.
- **Polytherapy** in pregnancy is defined as treatment episodes of ≥ 2 distinct ASMs in the first trimester that both take ≥ 3 months.
- **Switching** during pregnancy is defined as a particular ASM treatment episode in the year prior to pregnancy that ends before the pregnancy period, and initiation of a different ASM in one of the three trimesters.

Within pregnancy we will also assess dose changes of ASM, as below:

- **Dose changes of ASMs** will be estimated among the pregnant women who continue on ASMs (including continuous ASM use and late discontinuation), based on comparison of prescribed/dispensed mean weighted daily dose (in DDD per day equivalent) in 3-months before pregnancy to those in 1st, 2nd, and 3rd trimesters.

10.4.3 Covariates

10.4.3.1 Age groups

The different age groups considered in this study for stratifications purposes in various objectives are:

- 12.0 – 18.9 years old (for both women and men)
- 19.0 – 34.9 years old (for both women and men)
- 35.0 – 54.9 years old (for both women and men)
- 55.0 – 74.9 (for men)
- 75.0 and older (for men)

10.4.3.2 Indications for ASM exposure

We will include the following indications of the exposure drugs, which will be used for stratifying the analyses in various sub-objectives: Epilepsy, bipolar disorder, prevention of migraine attacks, generalised anxiety disorder, neuropathic pain (or nociplastic, centralised pain, or fibromyalgia), essential tremor, restless legs syndrome, major depression, and schizophrenia (psychosis). To detect indications from electronic medical records in diverse data sources, we will search for indicators of primary indications (only through diagnostic codes) in the 1-year look-back period, based on a priority list and algorithm previously developed by ConcePTION. Multiple indications may be found for each person.

10.4.3.3 Key comorbidities

The following list of key comorbidities will be used for stratifying the analyses of sub- objective 1.2. These include the most common comorbidities that patients with epilepsy or those who use ASM might have:³⁷ Each of these co-morbidities will be identified by diagnostic codes and medications as proxies in the look-back period.

- Cognitive impairment and dementia.
- Sleep disorders (including obstructive sleep apnoea and insomnia).
- Hypertension (or use of anti-hypertensives).

- Cardiovascular diseases (including myocardial infarction and stroke).
- Respiratory disease (asthma and chronic obstructive pulmonary disease, or use of bronchodilating agents).
- Bone disease and fractures.
- Brain injury.
- Hypoxia.

10.5 Data sources

The main characteristics of participating DEAPs are presented in Table 2.

10.5.1 Spain (ES): VID (Valencia)

The Valencia health system integrated database (VID) is a set of multiple, public, population-wide electronic databases for the Valencia Region, the fourth most populated Spanish region, with ≈ 5 million inhabitants and an annual birth cohort of 48000 new-borns, representing 10.7% of the Spanish population and around 1% of the European population.³⁸ The VID provides exhaustive longitudinal information including sociodemographic and administrative data (sex, age, nationality, etc.), clinical (diagnoses, procedures, diagnostic tests, imaging, etc.), pharmaceutical (prescription, dispensation) and healthcare utilisation data from hospital care, emergency care departments, specialized care (including mental and obstetrics care), primary care and other public health services.³⁹ It also includes a set of associated population databases and registries of significant care areas such as cancer, rare diseases, vaccines, congenital anomalies, microbiology and others, and public health databases from the population screening programmes. All electronic health systems in the VID use the ICD-9-CM and the ICD-10-CM. All the information in the VID databases can be linked at the individual level through a single personal identification code. The databases were initiated at different moments in time, but all in all the VID provides comprehensive individual-level data fed by all the databases from 2008 to date. Information on PCR test results as well as serological/antibody tests results for the whole population of the Valencia region is available and linkable from the Microbiological Surveillance Network (RedMIVA). The Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO) is Data Access Provider for VID. The ConcePTION pregnancy identification algorithm has already been used in VID. The results were compared with official statistics and within the knowledge gained from the source tables, with good agreement and confidence in the calculated pregnancy periods for the green, yellow and blue pregnancies.

10.5.2 Spain (ES): SIDIAP (Catalonia)

The Information System for the Development of Research in Primary Care (Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària, SIDIAP) in Catalonia, Spain, is a primary care database set up by the Institute of Research in Primary Care (Institut Universitari D'Investigació en Atenció Primària Jordi Gol [IDIAPJGol]) and Catalan Institute of Health (Institut Català de la Salut) (<https://www.sidiap.org/>). The database collects information from 228 primary health care centres and includes more than 5.8 million patients covered by the Catalan Institute of Health (approximately 78% of the Catalan population) and is highly representative of the Catalan population.⁴⁰ SIDIAP data comprise the clinical and referral events registered by primary care health professionals (i.e., GPs, paediatricians, gynaecologists, midwives and nurses) and administrative staff in electronic medical records, comprehensive demographic information, community pharmacy invoicing data, specialist referrals, and primary care laboratory test results.⁴⁰ SIDIAP can also be linked to other data sources, such as the hospital discharge database, on a project-by-project basis. Health professionals gather this information using ICD-10-CM codes, ATC codes, and structured forms designed for the collection of variables relevant to primary care clinical management, such as country of origin, sex, age, height, weight, body mass index, tobacco and alcohol use, blood pressure measurements, and blood urine test results. SIDIAP is listed under the HMA-EMA catalogue of real world-data sources and studies.⁴¹ The ConcePTION pregnancy algorithm to identify pregnancies has been previously used within SIDIAP. Approximately 50% to 60% of pregnant women in Catalonia are attended in the sexual and reproductive

healthcare centres that contribute data to SIDIAP. Approximately 70% of infant records can be linked to maternal records and used for research.

10.5.3 Norway (NO): Norwegian data registries

The core data that UIO has access to are the health care administrative data banks of the entire Norwegian population, which amounts to approximately 5.3 million inhabitants.⁴² Norway has a universal public health care system, consisting of primary health care services and specialist healthcare services. Many population-based health registries were established in the 1960s, with use of unique personal identifiers facilitating linkage between registries. The mandatory national health registries were established to maintain national functions. They are used for health analysis, health statistics, improving the quality of healthcare, research, administration and emergency preparedness. Information about all Norwegian National Registries can be found here: www.fhi.no/en/more/access-to-data/about-the-national-health-registries2/. The Norwegian data sources in this project are the national mandatory Medical Birth Registry linked to the prescription registry and patient registries covering the secondary care (the National Patient Register) and the primary care (Norway Control and Payment of Health Reimbursement). The data set that will be used in this project has already been mapped onto the ConcePTION CDM, passed Data characterisation (quality checks). Moreover, the ConcePTION pregnancy algorithm has been quality assured on this data set (coverage 2008–2021).

10.5.4 United Kingdom (UK): CPRD

The CPRD is collated with the computerised medical records of GPs in the UK, who act as gatekeepers of the healthcare system and maintain patients' life-long electronic health records.⁴³ Here, GPs are not only responsible for primary health care and specialist referrals, but they also store information about those referrals and hospitalisations. Secondary care teams also provide information to GPs about their patients, including key diagnoses. CPRD is one of the largest primary care databases in the world, where it currently includes data on approximately 60 million individuals (acceptable for research purposes), of which 18 million are currently active (i.e., still alive and registered with the GP practice) with at least 20 years of follow-up for 25% of the patients, in over 2000 primary care practices across the country (<https://cprd.com/Data>). Both CPRD GOLD and Aurum databases will be used. The data recorded in the CPRD include demographic information, clinical events (signs, symptoms, diagnoses), prescription details, preventive care, immunisation, consultations (e.g., phone calls, letters, e-mails, in surgery, at home), laboratory tests, specialist referrals, hospital admissions, and major outcomes, including death.⁴⁴ CPRD data is coded using Read or SNOMED codes. Furthermore, validation studies are conducted regularly by comparing recorded data to written notes of general practitioners.⁴⁵ The population in the data source is generalisable to the UK population based on age, sex, socioeconomic class, and national geographic coverage. For the majority of the CPRD practices (>80%), the CPRD primary care data can be linked at the patient level to Hospital Episode Statistics (HES). HES includes all admission data to National Health Service (NHS) hospitals in England and private providers funded by NHS since 1997.⁴⁶ This dataset contains information on admission, discharge dates, diagnoses, specialist visits, and medical procedures. The diagnoses are classified based on the International Classification of Disease (ICD)-10 clinical coding system. Office for National Statistics (ONS) mortality data recording causes of death from death certificates are collated by ONS and routinely linked to CPRD and HES. Of relevance for this proposal, collaborative work between LSHTM and CPRD researchers has recently established a pregnancy register within the CPRD, identifying instances of pregnancy and pregnancy outcomes since 1987. The CPRD is listed under the ENCePP resources database, and access will be provided by Utrecht University, who has a licence to use CPRD data with HES linkage.

10.5.5 Finland (FI): Finnish Health Registries

Universal health insurance is accessible for all citizens and permanent residents in Finland. Wellbeing services counties (n=22) are responsible for arranging health care funded by state. Health services are divided into primary health care and specialised medical care. The data that THL provides access to is most healthcare registries covering the whole population of Finland (around 5.6 million inhabitants).

The core data of the Drugs and Pregnancy project (<https://thl.fi/en/research-and-development/research-and-projects/drugs-and-pregnancy>) includes data from Medical Birth Register, Register of Congenital Malformations and Register of Induced Abortions from 1996 onwards. Drugs and Pregnancy Database also includes following registries maintained by the Kela: Special refund codes and diagnoses three months before pregnancy to three months following delivery or abortion and reimbursed drug refills three months before pregnancy to three months following delivery or abortion also 1996 onwards. Electronic prescriptions and refills linked to pregnancy data is available one year before pregnancy and six months after delivery from 2017 onwards. Drugs and Pregnancy Database currently includes all pregnancies ending in delivery or induced abortion in 1996-2022 the total amount being around 1.7 million pregnancies. Additional data sources maintained or accessed by THL and previously mapped to ConcePTION CDM are Care Register for Health Care (HILMO), Register of Primary Health Care visits (Avohilmo), Cause of Death Registry for infant and maternal deaths. These data sources have been extensively used in registry-based research.⁴⁷⁻⁵⁰ Data collection is mandatory by law and does not require informed consent from the recorded subjects. Data is stored on an individual level and can be linked by the personal identification number assigned to all citizens and permanent residents in Finland at birth or upon immigration. The PROMPT stream of ConcePTION pregnancy identification algorithm has been used at THL. The results were reviewed against the subject knowledge from the source tables and good agreement obtained for included pregnancy periods with green and yellow quality.

10.5.6 France (FR): EFEMERIS

EFEMERIS is a cohort of pregnant women covered by the French Health Insurance System in Haute-Garonne (South-west France), built to conduct drug utilisation and medication safety studies in pregnant women (www.efemeris.fr).⁵¹ EFEMERIS data collection started in July 2004. It is ongoing and updated once a year. EFEMERIS comprises data on: all prescriptions redeemed in out-patient pharmacies, prior to and during pregnancy; administrative and medical data about the mother and the child through children's certificates filled in during the compulsory medical examinations at birth, 9 and 24 months; data about Terminations Of Pregnancy for Foetal Anomaly (TOPFAs); and the nature and date of termination of pregnancy (elective termination, stillbirth, and spontaneous abortion).⁵²

This was approved by the French Data Protection Agency on 7 April 2005 (authorisation number 05-1140). Everyone requesting data access and doing statistical analyses are signing a confidentiality agreement form. All requests need to include at least one EFEMERIS investigator. Access requests to EFEMERIS for research purpose must be approved by the Steering Committee and data providers. Currently data on 180,458 mother-outcome pairs are recorded in EFEMERIS for the period between mid-2004 to end of 2021. Part of the EFEMERIS dataset (only data from 2004-2013) has been linked with the RHE31 dataset (Haute-Garonne Child Disability Registry), providing exhaustive data about validated medical diagnosis of severe NDD at the age of 5 and/or 8 years. The disabilities registered in the REH31 include autism spectrum disorders (ASD), pervasive developmental disorders (PDD), severe sensory impairments, motor disabilities and trisomy 21. The French POMME [Prescription-Drugs-Mothers-Children] cohorts hold anonymised data on children from conception and during their childhood. POMME cohorts are subsets of EFEMERIS data where the children are followed up over time, it includes children born between 1 July 2010 and 30 June 2011 (POMME-2010) and between 1 July 2015 and 20 June 2016 (POMME-2015). POMME-2010 includes more than 8000 children and POMME-2015 more than 10,000 children. The cohorts are updated annually. Currently, available data concern children until 10 years of age for the POMME-2010 cohort and until 5 years of age for the POMME-2015 cohort. In addition to data already collected in EFEMERIS, POMMEs records data on medicines and medical care prescribed and reimbursed to the children during childhood. (<http://www.efemeris.fr/communications.html>). The datasets that will be used in this project have already been mapped onto the ConcePTION CDM, passed Data characterisation (quality checks). Moreover, the ConcePTION pregnancy algorithm has been quality assured on this data set.

10.5.7 Italy (IT): VAL PADANA LHU

The Val Padana LHU database is a claims database containing patient-level data from the provinces of Mantova and Cremona, in Lombardy region. The coverage of this database is high: from 2008 to 2024, the catchment area population consists of more than 780,000 persons (7.8% of the Lombardy regional population). The Val Padana linkage database consists of several datasets which are linked through a unique patient identifier: a demographic registry, pharmacy claims database with information on concerning all dispensed drugs reimbursed by the Italian NHS, as well as hospital discharge diagnose databases, emergency department admissions database, claims for diagnostic and laboratory tests ordered, and a registry of patients exempt from healthcare service co-payment (e.g. diabetes mellitus, dementia, and other chronic diseases). Birth registry is also available; it provides mother-child linkage and information on child and maternal healthcare as well as sociodemographic data and risk factors. Moreover, all ADRs registered at birth are traceable from the birth registry. There is no algorithm to identify the beginning of a pregnancy. Val Padana LHU is full member of the European network of population-based registries for the epidemiological surveillance of congenital anomalies (EUROCAT). Val Padana Registry includes cases of congenital anomalies in live births, stillbirths and TOPFA (Terminations of Pregnancy for Foetal Anomaly) that occurred in the first year of life since 2002 (Mantova province) and 2008 (Cremona province). Data is updated to 2020. Patient level data from these claims databases, including other drugs reimbursed by the NHS and dispensed by community pharmacies, can be linked together, using a unique patient identifier. The healthcare information in the databases is coded using international coding systems, such as ICD-9-CM for diagnoses and ATC classification for drugs.

10.5.8 SPAIN (ES): BIFAP

BIFAP (Base de Datos para la Investigación Farmacoepidemiológica en el Ámbito Público), a computerised database of medical records of primary care (www.bifap.aemps.es),^{53,54} is a non-profit research project funded by the Spanish Agency for Medicines and Medical Devices (AEMPS). BIFAP is listed under the ENCePP resources databases (Data source ID 21501). The project started in 2001 and currently includes anonymised clinical and prescription/dispensing data on 22 million (17 active population) patients with clinical information from 15,373 physicians (GPs and paediatricians) from nine participant Autonomous Regions. Those patients represent 94% of the population in participating regions, and 37% of the total Spanish population. Mean duration of follow up in the database is 10 years. Information collected by PCPs includes administrative, socio-demographic, lifestyle, and other general data, clinical diagnosis and health problems, results of diagnostic procedures, interventions, and prescriptions/dispensations. Diagnoses are classified according to the International Classification of Primary Care (ICPC)-2, ICD-9CM and SNOMEDCT system, and a variable proportion of clinical information is registered in “medical notes” in free text fields in the EMR. Additionally, information on hospital discharge diagnoses coded in ICD-10 terminology as well as public specialist prescribing are linked to patients included in BIFAP for a subset of periods and regions participating in the database. All information on prescriptions of medicines by the PCP is incorporated and linked by the PCP to a health problem (episode of care), and information on the dispensing of medicines at pharmacies is extracted from the e-prescription system that is widely implemented in Spain. A mother-child linkage has not been established so far and several options are being exploring with the regional data providers to research in the medium-term. Therefore, BIFAP will participate in specific objectives only.

In BIFAP, two different pregnancy algorithms have been developed and tested: 1) the ConcePTION algorithm retrieved almost 2 million pregnancies between 2008-2021 from primary and hospital medical records. Pregnancy episodes including ongoing pregnancies and pregnancies with and without (may include early spontaneous abortions) unknown outcomes, could be identified; 2) Furthermore, a previous study has demonstrated the usefulness of BIFAP database for studies on drug utilisation during pregnancy (regardless the outcome) using an in-house developed pregnancy-algorithm with the collaboration of experts in the field.⁵⁵

10.6 Study size

The study comprises information on over 69.6 million active subjects as source population, among those the majority will be part of the base population of women and men of childbearing age. For different sub-objectives the size of the population will differ, but we have no specific hypothesis to test and therefore no specific sample size calculation is required.

10.7 Data management

The study will be conducted in a distributed manner using the EU PE&PV, ConcepTION, UMCU, ARS and VAC4EU tools, procedures, and pipeline. Figure 4 depicts this pipeline from a programming perspective, specifying the data sets (D) and transformation processes (T). Programming follows this pipeline, with involvement of different types of experts.




Figure 4. RWE data transformation pipeline from a programming perspective. T: transformation steps, D: data sets.

D1: Original data can be in any native format

The RWD-RWE pipeline used by EU PE&PV, ConcepTION, and VAC4EU starts with data banks that are controlled by DAPs. These can be in any format and data stays local. The ETL design is shared in a searchable FAIR catalogue. The ConcepTION Molgenis data catalogue is a metadata management tool designed to contain searchable meta-data describing organisations that can provide access to specific data sources.

T1: Syntactic harmonisation (ETL)

Syntactic harmonisation is conducted through an extraction, transformation, and loading (ETL) process of native data into the requested CDM. To harmonise the structure of the data sets stored and maintained by each data partner, a shared syntactic foundation is used. The ETL process has various structured steps as described by Thurin et al.⁵⁹ Metadata (descriptive data about the data sources and databanks) & data dictionaries, are uploaded in ConcepTION data catalogue.

D2: Common Data Model

For this project, the CDM (D2) of the ConcePTION pipeline, version v2.2., will be utilised, which is available as an open-source CDM. In this CDM, data are represented in a common structure, but the values of the data remain in their original language (e.g. codes will have either ICD9/10//Read codes/ICPC/ Italian code system for exemptions values).

T2: Semantic harmonisation

During the T2 step, many data transformations occur related to the completion of missing features in the data. Based on the relevant diagnostic medical codes and keywords, as well as other relevant concepts (e.g., medications), one or more *phenotype algorithms* are constructed (typically one sensitive, or broad, algorithm and one specific, or narrow, algorithm) to operationalise the identification and measurement of each event. In this step we conduct time anchoring (observation periods, look back periods), clean the data, sort on record level, aggregate across multiple records, and combine concepts for implantation of algorithms, and rule-based creation of study variables.

In this phase of creation of study variables, the semantic mapping is conducted. This semantic mapping across different vocabularies is conducted as part of the R-study script using different functionalities. To reconcile differences between different terminologies and native data availability, machine readable code lists are used that comprise the terminologies that are used in the network (e.g. ICD-9, ICD10, SNOMED, ICPC and DEAP specific adaptations). This is combined with the BRIDGE metadata file that defines risk windows, look-back periods, and algorithms for each study variable.⁶⁰

D3: Study variables

D3 datasets are interim data sets with information on study variables for each study participant, the unit may be a person, a medicine, or episode of time. The design of these datasets is described in codebooks. Examples of D3 datasets are the outputs of the ConcePTION pregnancy algorithm, functions that define smoking. Multiple functions/packages exist for different study variables.

T3: Application of epidemiological design

In the T3 step epidemiological designs are applied such as sampling, matching (on specific variables and/or propensity scores), and selection based on inclusion and exclusion criteria using the study variables in the D3 datasets. The designs will be implemented for the various study objectives using R-scripts, and these may use the existing functions (R-cran) or functions that have been developed in the VAC4EU and ConcePTION community.

D4: Analytical data set

D4 is an analytical dataset, and multiple D4 data sets may be produced based on the objectives of the study. The format is described initially in a code book for communication between programmers and statisticians.

T4: Statistical analysis

This step in the data transformation pipeline will produce statistical estimates such as descriptives

(counts, percentages), distributions (mean, percentiles), rates (prevalence, incidence), regression coefficients, or other relevant estimates. This will be conducted using R.

D5: Results

D5 is the set of estimands, tables or aggregate data. The aggregated results produced by these scripts at the DAPs site will be uploaded to the UMCU Digital Research Environment (DRE) for post-processing, pooling and visualisation (see Figure 4). The DRE is a cloud-based, globally available research environment where data are stored and organised securely and where researchers can collaborate. The DRE is made available through UMCU ([The anDREa consortium 2021](#)). The DRE applies double authentication where researchers can collaborate using data that are stored and organised securely. UMC Utrecht is responsible for data processing and data security.

All researchers who need access to the DRE will be granted access to study-specific secure workspaces by UMCU. Access to the workspaces will be possible only after double authentication using an identification code and password together with the user's mobile phone for authentication.

Uploading of files will be possible for all researchers with access to the workspace within the DRE. Downloading of files will be possible only after requesting and receiving permission from a workspace member with an "owner" role, who will be a UMCU team member.

T5: Post-processing/ pooling

In this step, the result from different DEAPs will be pooled and converted in tables and figures for reporting.

Scripting and deployment

The analytical R scripts that produce the T2-T4 steps are produced on institutional GitHubs for version control. Links to the latest script will be distributed to DEAPs for local deployment. Any issues can be notified on the private GitHub, and the data engineers who are responsible for the R code will work with the local DEAP to resolve issues if they occur. After the final report is accepted the script will be made publicly available through GitHub and get a digital object identifier through Zenodo platform.

10.8 Data analysis

All scripts will be coded based on the data transformation pipeline described in Figure 4 in R. An overview of numerators and denominators used to calculate outcome measures for each sub-objective is provided in the simple statistical analysis plan (SAP) in Table 6.

Sub-objective 1.1

Incidence and prevalence rates of ASM use will be calculated in the total population among both women and men of childbearing potential for individual drug substances, and by ASM sub-group. Annual incidence and prevalence rates of ASM use will be estimated over the study period, for each data source, and stratified by age group, indication, and calendar year. For incidence rates per calendar year, we will use a look-back period of one year of no ASM use. A person will be counted as an incident (or new) user in a specific year if they have a first prescription that year, also considering the 1-year look-back period. Subjects will be counted as prevalent (or current) users of ASMs in a year if they start a

prescription or were on a prescription that year. The duration of the prescription should cover at least one day of that year.

Table 6. Simple Statistical Analysis Plan (SAP) for ADEPT study Objective 1

Sub-objective 1.1: To estimate the annual incidence and prevalence rate of ASM use in women of childbearing age (12-55 years of age) and men (12 years and older) (population base cohort).

Sub-objective 1.1: Incidence rate			
Measure	Numerator	Denominator	Example format, unit
Annual incidence rate of ASM use	Number of individuals with ≥ 1 treatment episode of an ASM within a calendar year and without an overlapping treatment episode during the 1-year look-back period	Total number of individuals in that calendar year in the data source	10 per 1,000 person-year among men of childbearing age, or 1% in year 2016
Stratification by	Individual drug substance, drug sub-groups,* age groups (drug sub-groups), indication, calendar year, data source		

* Drug-subgroups include: Older ASM, newer ASMs, gabapentinoids, and benzodiazepines with epileptic properties.

Sub-objective 1.1: Prevalence rate			
Measure	Numerator	Denominator	Example format, unit
Annual prevalence rate of ASM use	Number of individuals with ≥ 1 treatment episode of an ASM within a calendar year (see above)	Total number of individuals in that calendar year in the data source	25 per 1,000 women of childbearing potential, or 2.5% in year 2016
Stratification by	Individual drug substance, drug sub-groups,* age groups (drug sub-groups), indication, calendar year, data source		

* Drug-subgroups include: Older ASM, newer ASMs, gabapentinoids, and benzodiazepines with epileptic properties.

Sub-objective 1.2 To describe treatment duration, discontinuation, and treatment switches to other ASMs or alternative medications and polytherapy in women of childbearing age (12-55 years of age) and men (12 years and older) who receive a new ASM prescription/dispensing in a specific calendar year (ASM user cohort).

Sub-objective 1.2: Treatment duration		
Measure	Calculation	Example format, unit
Overall treatment duration of ASM	Mean, median, minimum, maximum, interquartile range, and SD (in months) of treatment episodes for all individuals with ≥ 1 treatment episode of an ASM across the study period in the data source	Mean: 15 months (SD 23), median: 18 months (range 1-100) use in men
Stratification by	Individual drugs, data source	

Sub-objective 1.2: Discontinuation rate			
Measure	Numerator	Denominator	Example format, unit
Annual discontinuation rate of ASM	Discontinuers: Number of individuals who have a gap of ≥ 120 days between treatment episodes of an ASM in each calendar year	The number of prevalent ASM users in that calendar year in the data source (see above)	11% of the prevalent users discontinued in year 2014
Stratification by	Individual drug substance, drug sub-groups,* age groups, calendar year, data source		

* Drug-subgroups include: Older ASM, newer ASMs, gabapentinoids, and benzodiazepines with epileptic properties.

Sub-objective 1.2: Alternative medications
--

Measure	Numerator	Denominator	Example format, unit
Annual rate of alternative medication use	Number of individuals with ≥ 1 prescription/dispensing of all alternative medications for each indication of interest within a calendar year in the data source	Total number of person-time in that calendar year in the data source	5 per 1,000 women of childbearing age who used drug for bipolar disorder, or 0.5% in year 2015

Sub-objective 1.2: Switching rate			
Measure	Numerator	Denominator	Example format, unit
Annual switching rate from one ASM to another ASM or to an alternative medication	Total number of individuals who have ≥ 1 treatment episode for a specific ASM and discontinued, with ≥ 1 treatment episode for a different ASM or alternative medication, during the last treatment episode of the ASM or within the discontinuation period of the ASM in each calendar year	The number of prevalent ASM users in that calendar year in the data source (see above)	4.5% of the prevalent users of topiramate in year 2011
Stratification by	Individual drug substances, calendar year, data source		

Sub-objective 1.2: Polytherapy rate			
Measure	Numerator	Denominator	Example format, unit
Annual polytherapy rate of ASM	The number of individuals who use ≥ 2 distinct ASMs in a calendar year with ≥ 182 days overlap between the treatment episodes	Total number of study population in that calendar year in the data source	17 per 1000 men of childbearing potential, or 1.7% in year 2013
Stratification by	Indications, calendar year, data source		

Sub-objective 1.3: To estimate pre-pregnancy ASM use, and initiation and continuous use of ASMs during the pregnancy period.

Sub-objective 1.3: Pre-pregnancy use rate			
Measure	Numerator	Denominator	Example format, unit
Annual pre-pregnancy ASM use rate	The number of unique pregnancies with ≥ 1 treatment episodes in the year prior to pregnancy, falling within both 12-6 months before pregnancy and 6-0 months before pregnancy.	Total number of unique pregnancies in that calendar year in the data source	14 per 1000 pregnancies, or 1.4% in year 2010
Stratification by	Individual drug substance, drug sub-groups,* calendar year, data source		

* Drug-subgroups include: Older ASM, newer ASMs, gabapentinoids, and benzodiazepines with epileptic properties.

Sub-objective 1.3: Initiation rate during pregnancy			
Measure	Numerator	Denominator	Example format, unit
Annual initiation rate of ASM during pregnancy	Number of pregnancies in a calendar year with ≥ 1 treatment episode of an ASM during any trimester, but no treatment episode in the 12 months prior to pregnancy start	Total number of pregnancies in that calendar year in the data source	8 per 1000 pregnancies, or 0.8% in year 2014
Stratification by	Individual drug substance, drug sub-groups,* age groups (all exposure drugs and subgroups), indication, calendar year, data source		

* Drug-subgroups include: Older ASM, newer ASMs, gabapentinoids, and benzodiazepines with epileptic properties.

Sub-objective 1.3: Continuous use rate			
Measure	Numerator	Denominator	Example format, unit
Annual continuous rate of ASM use during pregnancy	The number of pre-pregnancy users of an ASM within a calendar year that also runs into the first, AND second AND third trimester of pregnancy	Total number of pregnancies in that calendar year in the data source	22 per 1000 pregnancies, or 2.2% in year 2019

Stratification by	Individual drug substance, drug sub-groups,* indication, calendar year, data source
--------------------------	---

* Drug-subgroups include: Older ASM, newer ASMs, gabapentinoids, and benzodiazepines with epileptic properties.

Sub-objective 1.4: To estimate pre-pregnancy, early and late discontinuation of ASMs, treatment switches to other ASMs or alternative medications and polytherapy among pregnant women.

Sub-objective 1.4: Discontinuation rates during pregnancy			
Measure	Numerator	Denominator	Example format, unit
Annual pre-pregnancy discontinuation rate of ASM	The number of pre-pregnancy users of an ASM within a calendar year (see above) that does not run into the pregnancy period	Total number of pre-pregnancy users of an ASM in a calendar year in the data source (see above)	620 per 1000 pre-pregnancy use, or 62% in year 2015
Annual early discontinuation rate of ASM during pregnancy	The number of pre-pregnancy users of an ASM within a calendar year (see above) that continued to 1 st trimester only.	Total number of pre-pregnancy users of an ASM in a calendar year in the data source (see above)	130 per 1000 pre-pregnancy use, or 13% in year 2008
Annual late discontinuation rate of ASM during pregnancy	The number of pre-pregnancy users of an ASM within a calendar year (see above) that continued to 2 nd trimester only.	Total number of pre-pregnancy users of an ASM in a calendar year in the data source (see above)	60 per 1000 pre-pregnancy use, or 6% in year 2002
Stratification by	Individual drug substance, drug sub-groups,* calendar year, data source		

* Drug-subgroups include: Older ASM, newer ASMs, gabapentinoids, and benzodiazepines with epileptic properties.

Sub-objective 1.4: Switching rate during pregnancy			
Measure	Numerator	Denominator	Example format, unit
Switching rate from one ASM to a different ASM or to an alternative medication during pregnancy	The number of pre-pregnancy users of an ASM within a calendar year (see above) that switched to a different ASM or alternative medication during the pregnancy period	Total number of pre-pregnancy users of an ASM in a calendar year in the data source (see above)	10 per 1000 pre-pregnancy use, or 1% in year 2017
Stratification by	Individual drug substance, calendar year, data source		

Sub-objective 1.4: Polytherapy rate during pregnancy			
Measure	Numerator	Denominator	Example format, unit
Polytherapy rate during pregnancy	The number of pregnancies with ≥ 2 distinct ASM treatment episodes taken concurrently for ≥ 3 months during the pregnancy period	Total number of pre-pregnancy users of an ASM in a calendar year in the data source (see above)	11 per 1000 pregnancies, or 1.1% in year 2012
Stratification by	Indication, calendar year, data source		

Sub-objective 1.5: To estimate dose changes of ASMs in women prior to and during pregnancy.

Sub-objective 1.5: Mean weighted daily dose of ASM - 3-month before pregnancy			
Measure	Numerator	Denominator	Example format, unit
Annual proportion of pregnancies with low, middle, and high DDD of ASM during pre-pregnancy	Total number of pregnant women who are continuous users of ASM during pregnancy or late discontinuers of ASM during pregnancy in a calendar year in the data source (see above) which have a mean daily dose value of <0.5 (low), $0.5-1.49$ (middle), and ≥ 1.5 DDD (high) in 3-months before pregnancy	Total number of ASM users during pregnancy (i.e., continuous users, and late discontinuers) in that calendar year in the data source	Low use of topiramate: 60%, Middle use: 20% High use: 20%, in 3-months before pregnancy in year 2005
Stratification by	Individual drug substance, calendar year, data source		

Sub-objective 1.5: Mean weighted daily dose of ASM – 1 st trimester			
Measure	Numerator	Denominator	Example format, unit
Annual proportion of pregnancies with low, middle, and high DDD of ASM during 1 st trimester	Total number of pregnant women who are either continuous users of ASM during pregnancy or late discontinuers of ASM during pregnancy in a calendar year in the data source which have a mean daily dose value of <0.5 (low), 0.5-1.49 (middle), and ≥1.5 DDD (high) during the 1 st trimester	Total number of ASM users during pregnancy (i.e., continuous users, and late discontinuers) in that calendar year in the data source	Low: 10% Middle: 70% High: 20% use of valproate in the 1 st trimester in year 2004
Stratification by	Individual drug substance, calendar year, data source		

Sub-objective 1.5: Mean weighted daily dose of ASM – 2 nd trimester			
Measure	Numerator	Denominator	Example format, unit
Annual proportion of pregnancies with low, middle, and high DDD of ASM during 2 nd trimester	Total number of pregnant women who are either continuous users of ASM during pregnancy or late discontinuers of ASM during pregnancy in a calendar year in the data source which have a mean daily dose value of <0.5 (low), 0.5-1.49 (middle), and ≥1.5 DDD (high) during the 2 nd trimester	Total number of ASM users during pregnancy (i.e., continuous users, and late discontinuers) in that calendar year in the data source	Low: 80% Middle: 10% High: 10% use of lamotrigine in 2 nd trimester in year 2006
Stratification by	Individual drug substance, calendar year, data source		

Sub-objective 1.5: Mean weighted daily dose of ASM – 3 rd trimester			
Measure	Numerator	Denominator	Example format, unit
Annual proportion of pregnancies with low, middle, and high DDD of ASM during 3 rd trimester	Total number of pregnant women who are either continuous users of ASM during pregnancy or late discontinuers of ASM during pregnancy in a calendar year in the data source which have a mean daily dose value of <0.5 (low), 0.5-1.49 (middle), and ≥1.5 DDD (high) during the 3 rd trimester	Total number of ASM users during pregnancy (i.e., continuous users, and late discontinuers) in that calendar year in the data source	Low: 25% Middle: 70% High: 5% use of gabapentin in 3 rd trimester in year 2011
Stratification by	Individual drug substance,* calendar year, data source		

*This analysis will be only performed on eight ASMs of special interest, including: valproate (N03AG01), carbamazepine (N03AF01), phenobarbital (N03AA02), lamotrigine (N03AX09), topiramate (N03AX11), levetiracetam (N03AX14), clonazepam (N03AE01), gabapentin (N02BF01).

Attrition tables

Attrition: Base cohort		
Measure*	Count	Example format, unit
Total instance population	Number of individuals in the source population (all individuals included in data source during the study period (1/1/2000-latest availability))	7,800,000 individuals in CPRD during the study period.
Sex not defined	Number of individuals within the source population for which sex is not defined as either male or female.	123 individuals excluded from dataset due to sex not defined.
Birth date incomplete	Number of individuals within the source population for which year of birth is missing or incomplete.	327 individuals excluded from dataset due to the birth date being incomplete.
Death date incomplete	Number of individuals within the source population for which year of death is	26 individuals excluded from dataset due to the death date being incomplete.

	missing in the case that death has been recorded.	
Incomplete observation periods	Number of individuals within the source population without at least one year of available data in the data source.	972 individuals excluded from dataset due to incomplete observation period.
Individuals <12 years of age at last data availability	Number of individuals within the source population for which age at date of last data availability is less than 12 years.	5,748 individuals excluded from dataset due to being less than 12 years at last data availability.
Women >55 years of age at start date of observation	Number of women within the source population for which age at start date of observation is greater than 55 years.	354,000 women excluded from dataset due to being greater than 55 years at start date of observation.
Total population (Base cohort)	All women and men of childbearing age (must meet all inclusion criteria above).	6,764,000 individuals included in the CPRD base cohort.

* All attrition measures will be reported by data source.

Attrition: ASM (new) user cohort		
Measure*	Count	Example format, unit
Total population (Base cohort)	All women and men of childbearing age (must meet all inclusion criteria in table above).	6,764,000 individuals included in the CPRD base cohort.
No (new) ASM prescription/dispensing within the study period	Number of individuals within the base cohort without at least 1 day of treatment episode for an ASM overlapping with the study period.	6,421,000 individuals excluded from dataset due to not having a treatment episode for an ASM within the study period.
ASM (new) user cohort	Individuals who are either incident or prevalent users of an ASM during the study period.	343,000 individuals included in the ASM (new) user cohort.

* All attrition measures will be reported by data source.

Attrition: Pregnancy cohort regardless of ASM, Pregnancy with ASM cohort		
Measure*	Count	Example format, unit
Total female population (Base cohort)	All women of childbearing age (must meet all inclusion criteria above).	3,287,000 females included in the CPRD base cohort.
No pregnancy start date within the follow-up period	Number of women within the base cohort without a pregnancy start date within the follow-up period.	1,882,000 individuals excluded from dataset due to pregnancy start date not being within the follow-up period.
No available data 12 months prior to the pregnancy start date [†]	Number of women within the base cohort without at least 12 months of available data prior to the pregnancy start date.	43,000 individuals excluded from dataset due to not having at least 12 months of available data before pregnancy start date.
Pregnancy cohort regardless of ASM	Number of pregnancies meeting the above listed inclusion criteria. A single woman may have multiple pregnancies.	1,934,000 pregnancies included in the CPRD Pregnancy cohort regardless of ASM.
No ASM use during or 12 months prior to the pregnancy [‡]	Number of individuals within the Pregnancy cohort regardless of ASM without at least 1 day of treatment episode for an ASM both during pregnancy and within 12 months prior to the pregnancy.	1,786,000 individuals excluded from dataset due to no ASM use during or prior to the pregnancy period.
Pregnancy with ASM cohort	Number of pregnancies within the Pregnancy cohort who have an ASM treatment episode during pregnancy or in the 12 months prior to pregnancy period. A single woman may have multiple pregnancies.	148,000 pregnancies included in the CPRD Pregnancy with ASM cohort.

* All attrition measures will be reported by data source.

[†] For Finnish registries and EFEMERIS, data must be available in the 3 months prior (Finnish registries) and 2.5 months prior (EFEMERIS) to the pregnancy start date.

[‡] ASM treatment episode must occur during pregnancy or in the 3 months prior (Finnish registries) or 2.5 months prior (EFEMERIS) to pregnancy start date.

For sub-group analysis, ASMs will be classified into 4 categories as presented in Table 7 below. This classification is based on a literature review, considering the market entry year of ASMs, and prior classifications in literature (as first, second, or third generation, conventional or new generation, etc.)^{67,68,69,70}. Also, out of these 4 sub-groups, 8 drugs of special interest will be selected (Table 7), which are usually the most common and/or most teratogenic ASMs in use for various indications according to literature.

Table 7. Sub-group classification of ASM.

n	Older antiepileptics	Newer antiepileptics	Gabapentinoids	Benzodiazepines	Drugs of special interest
1	Aminobutyric acid	Brivaracetam	Gabapentin	Clonazepam	Valproate
2	Barbexaclone	Carisbamate	Pregabalin	Diazepam	Carbamazepine
3	Beclamide	Cenobamate	Mirogabalin	Lorazepam	Phenytoin
4	Carbamazepine	Eslicarbazepine		Clobazam	Lamotrigine
5	Ethadione	Felbamate		Midazolam	Levetiracetam
6	Ethosuximide	Fenfluramine			Topiramate
7	Ethotoin	Fosphenytoin			Gabapentin
8	Mephenytoin	Ganaxolone			Clonazepam
9	Mesuximide	Lacosamide			
10	Metharbital	Lamotrigine			
11	Methylphenobarbital	Levetiracetam			
12	Paramethadione	Oxcarbazepine			
13	Phenacemide	Perampanel			
14	Pheneturide	Progabide			
15	Phenobarbital	Retigabine			
16	Phensuximide	Rufinamide			
17	Phenytoin	Stiripentol			
18	Primidone	Topiramate			
19	Sultiam	Vigabatrin			
20	Trimethadione	Zonisamide			
21	Valproate				
22	Valpromide				

Sub-objective 1.2

The duration of ASM use in the ASM user's cohort (i.e., all women and men of childbearing potential who used ASMs during study period) will be estimated based on the constructed treatment episodes for each individual ASM. The number of discontinuers of ASMs (individual drugs and subgroups) will be counted per year, for each DEAP, stratified by age group and calendar year. Annual discontinuation rates will be provided by dividing the number of discontinuers for each ASM and stratum by the total number of prevalent (current) users of the ASM in that stratum (of sex, age) per calendar year, for each DEAP. The use of alternative medications in prevalent users of ASMs will be counted during the study period as the yearly number of prescriptions/dispensings, for each DEAP, and will be reported separately for each of the indications of ASM. The annual incidence of treatment switches from an ASMs to another ASM or to an alternative medication will be estimated as the number of discontinuers who switch to an alternative treatment in a year divided by the total number of current ASM users that

year in each data source. The annual rate of polytherapy of ASMs will be estimated as the number of individuals who use ≥ 2 distinct ASMs in a calendar year with more than 6-months overlap between the treatment episodes divided by total number of study population in that calendar year in the data source. In the sensitivity analysis, the polytherapy analysis will be repeated considering a 120-days overlap between the treatment episodes of ≥ 2 ASMs. Please refer to the simple SAP in Table 6 for more information on the numerator/denominators.

Sub-objective 1.3

Here we will assess pre-pregnancy ASM use, initiation of ASMs during pregnancy, and continuous use of ASMs during pregnancy for individual drug substances and subgroups, among pregnant women. The estimations will be based on the constructed treatment episodes by the assumed treatment duration and AdhereR function. Annual rates of pre-pregnancy ASM use will be estimated, where the numerator is the number of unique pregnancies (not pregnant women) who had a treatment episode of an ASM in the year before pregnancy, falling within both 12-6 months before pregnancy and 6-0 months before pregnancy. Annual rates of initiation of ASMs during pregnancy will be calculated considering the number of pregnancies with an ASM treatment episode starting during any trimester, but no such ASM use (treatment episode) in the 12 months prior to pregnancy start. The annual rate of continuous use of ASMs will be calculated with the number of pregnancies with a pre-pregnancy ASM use that runs into the first, and second and third trimester. For all measures here (pre-pregnancy use, initiation, and continuous use ASM), the denominator is the total number of pregnancies in that year in the data source. For initiation and continuous use of ASMs, the rates will be stratified by indication. Please refer to the simple SAP in Table 6 for more information on the numerator/denominators.

Sub-objective 1.4

Pre-pregnancy discontinuation rates of ASMs, early and late discontinuation rates during pregnancy, polytherapy rates, and rate of switching from an ASM to another ASM or to an alternative medication among pregnant women will be estimated in all data sources. We will estimate annual pre-pregnancy discontinuation rates with the number of unique pregnancies who had pre-pregnancy ASM use that does not run into the pregnancy period in the numerator. Annual early and late discontinuation rates of ASM will be calculated with the number of unique pregnancies in each data source and calendar year with pre-pregnancy ASM use that continued to first and second trimesters only, respectively. The denominators for all discontinuation rates will be the total number of pre-pregnancy users of that ASM in that year per each data source (see above, Obj. 1-3). Annual rate of switching of ASMs is defined as the proportion of pre-pregnancy users of an ASM who started a different ASM or an alternative medicine during pregnancy period. Annual rates of overall polytherapy of ASM will be estimated as the number of pregnancies with a treatment episode of ≥ 2 distinct ASMs in the first trimester that both take ≥ 3 months, by the total number of pre-pregnant users in each data source and calendar year, stratified by indication. For more details, please refer to the simple SAP (Table 6).

Sub-objective 1.5

Finally, we will report dosage change patterns before and during pregnancy in those pregnant women who use ASMs around pregnancy, including continuous ASM users, and late discontinuers of ASMs. To implement this, we will calculate the total amount of drug used in each prescription/dispensing of the ASMs (only applied to drugs of special interest), using the number of tablets taken per day, potentially the number of packages dispensed, and the strength (dose) of the tablet in the EHR databases, or using the total number of DDDs dispensed in the administrative databases.

We will then calculate the overlap between each of the prescription/dispensing records with the fixed 3-months' time windows before and after pregnancy start date (aka trimesters). Based on the proportion of overlap (considering the assumed treatment duration of each record), the amount used in those fixed 3-months' time windows will be calculated. If there was more than 1 record in each time window, the used amounts will be summed. Then, the mean weighted daily dose of ASMs in the fixed 3-months' time windows before and after pregnancy will be estimated using the fixed length of each time window as denominator (91 days). We will categorize the calculated daily dose values of ASMs, based on the DDD per day with cut-offs as: low- (<0.5 DDD per day), mid- (0.5-1.49 DDD per day), and high-use (>1.5 DDD per day) for each individual. Finally, setting the start of pregnancy (from the pregnancy algorithm) as the 'transition point', we will investigate descriptively and visualised (in bar chart) the proportion of each stratum of the mean weighted daily doses of ASMs around pregnancy (i.e., from 3-months before the pregnancy to first, second and third trimesters). This was only done in data sources with a recorded prescribed dosing regimen, or at least with known data on the total amount of ASM used in each prescription/dispensation record. Please see the simple SAP (Table 6) for further information.

10.9 Quality control

Data sources will be transforming their data instances into the ConcePTION CDM as described above. To verify the correctness of the data instance, the INSIGHT quality checks,⁶¹ will be required to run. Level 1 and 2 checks are standardised quality check programs against the ConcePTION CDM that are publicly available with detailed SAPs, below:

- <https://github.com/UMC-Utrecht-RWE/INSIGHT-Level1>
- <https://github.com/UMC-Utrecht-RWE/INSIGHT-Level2>

Level 1 - Data completeness (including level 1b)

The purpose of the level 1 check is to verify the completeness of the ETL process and the data in the variables. Examples of tests are:

- Presence of variables in each of the CDM tables in D2
- Checks for misspelling and letter case in variable names in each of the CDM tables
- Verification of vocabularies
- Check date formats
- Check conventions of values
- Missing data analysis
- Frequency tables for categorical variables

Level 2 - Data logic/consistency

Real data is not random but follow certain logical constraints that reflect rules governing real-world situations. Examples of indicators generated by level 2 checks are:

- Event dates before date of birth.
- Event dates after date of death.
- Event dates out of observation periods.
- Subjects having an observation but not present in the PERSONS table.
- Observations associated with a visit id and occurred before/after the visit start/end date.
- Subjects younger than 12 years old reported as parents.
- Age at the observation period older than 115 y old

General approach to quality of R-coding

Data Management will follow standard operating procedures. R programs will be made available by UMC Utrecht (INSIGHT data quality checks), UU (analysis code) and ARS (Pregnancy algorithm). UU will create clear documentation of the data management steps.

Quality of study conduct

This research will be conducted according to the guidelines for Good Pharmacoepidemiology Practice (GPP) (International Society for Pharmacoepidemiology 2008) and according to the ENCePP code of conduct (European Medicines Agency 2018).^{62,63} All partners and principal investigators have experience in conducting pharmacovigilance/pharmacoepidemiological research and research is done by researchers trained in pharmacoepidemiology or pharmacovigilance. Utrecht University and University Medical Center Utrecht (data management) work according to a quality management system based on ISO 9001 principles and are certified.

All partners are ENCePP centres. The quality management system is system and process-oriented and based on continuous improvement. The system is based upon standard operating procedures implemented throughout the divisions with regular internal audits as well as external audits that lead to certification. The quality management system is based on national and international external quality requirements where available and pertinent, including the guidelines for Good Pharmacoepidemiological Practices, RECORD-PE, ENCePP Guide on Methodological Standards in Pharmacoepidemiology, Good Clinical Practice, and Good Clinical Data management. Practice as well as national and international guidelines and legislation concerning data-handling and privacy issues. All deliverables will be reviewed by project partners.

10.10 Limitations of the research methods

10.10.1. Limitations related to data sources

This proposal uses 8 available data sources, which capture different databanks and different underlying populations. The EFEMERIS and THL data source are cohorts of pregnancies, whereas other data banks are based on routine care, and record linkage. Although the data sources do not all capture the same type of information we will work with one protocol, a common data model and one script, to minimise heterogeneity. Previous work in CONSIGN has shown that it is possible to overcome the heterogeneity in the systems.⁶⁴ Using prescription/dispensing data on exposure drugs can automatically introduce misclassification of exposure bias, as there is no other information on actual use of medications, although repeated prescriptions may show actual use. This is especially concerning for gabapentinoids and particularly pregabalin, which unlike other ASMs have the potential to misuse, and the illicit drug use is normally not captured in EHDs.

Also, it may happen that misclassification affects the pregnancy cohort in various ways: 1) Persons may be classified as pregnant even if they are not. This is unlikely, because the ConcePTION Pregnancy Algorithm builds pregnancy episodes based on records that imply at face value that the person is pregnant at record date. But, it is not impossible. 2) Start date of the pregnancy may be misclassified. This may be a risk especially in pregnancy color-coded with ‘yellow’ or ‘red’, because start date has been imputed in such pregnancies, possibly based on a predictive model. The performance of the model will be assessed to evaluate the extent of misclassification. 3) End date of the pregnancy may be misclassified. This may be a risk especially in pregnancy color-coded with ‘yellow’ or ‘blue’, because end date has been imputed in such pregnancies. Moreover, the classification of type of end of pregnancy includes several unspecified types (e.g., ‘unknown’, ‘unfavourable outcome unspecified’). In data sources where pregnancies are detected at very early stages (namely, before the end of the first trimester) many pregnancies with unspecified outcome and color-coded as red may be interpreted as early pregnancy losses that did not need urgent medical attention (it is estimated that 80% of pregnancy losses occurs before the end of the first trimester).⁶⁵ To mitigate the risk of misclassification, samples of pregnancies included in the ConcePTION Pregnancy Algorithm output are manually verified by experts in the DAP’s organisation.

Additionally, not all data sources will capture details on prescribed dose of ASM, which means that prescription duration need to be based on a fixed duration or DDD based approach. These data sources cannot be used to look at dose changes. Another limitation could be data recency and data update times in different data sources that were included. However, a long study period (i.e., since 2000) would enable us to observe the trends in ASM use across almost two decades in all centres. The PHARMO Data Network's PPRN brings together data from various sources, with different data collection periods and catchment areas. Therefore, the final size and coverage of the study population for the Netherlands will depend on the databases included.

10.10.2. Limitations in proposed methodology

Our operational definitions of treatment episodes with a grace period of 30 days, temporary break (between 30-120 days of no new prescription/dispensing), ASM discontinuation (no new record after 90 days), and switching from an ASM to another ASM or an alternative medicine might not reflect the exact clinical scenarios in case of all ASMs, especially when using data from diverse EHDs. One especial case would be misclassification of prevalent users as incident users due to considering not long enough look-back periods. Due to this, we will not estimate incident use of ASMs among women and men of childbearing age and initiation of ASM during pregnancy in data sources EFEMERIS and THL that we only have 2.5 or 3-months look-back data for medications. But the overall approach is based on prior drug utilisation studies on the same topic,^{8,36} and same definitions for all ASMs across all centres, which considering the limitations and data quality will assist in comparability of findings.

Another limitation could be operational definitions for high, medium, and low daily doses of ASMs based on DDD data, which might not always reflect the actual clinical situation. But considering the diversity of data sources and healthcare systems involved, this seems the only feasible option in such a multi-database study. Also, capturing the right doses would be difficult when prescriptions are not renewed but patients were using the old prescription with new instructions from clinician, which is not visible in all our included data sources. This will be accounted for when interpreting findings from the dose analyses.

11 Protection of Human Subjects

This is a non-interventional study using secondary data collection and poses only very limited risks for individuals. Each research partner will apply for an independent ethical and/or institutional board review according to local regulations. Data protection and privacy regulations will be observed in collecting, forwarding, processing, and storing data from study participants.

Patient information

This study involves data that exists in a pseudonymized structured format locally and aggregated data centrally and contains no patient personal information. All parties will comply with all applicable laws, including laws regarding the implementation of organisational and technical measures to ensure the protection of patient personal data. Such measures will include omitting patient names or other directly identifiable data in any reports, publications, or other disclosures, except where required by applicable laws. Patient personal data will be stored at DAPs in encrypted electronic form and will be password protected to ensure that only authorised study staff have access. DAPs will implement appropriate technical and organisational measures to ensure that personal data can be recovered in the event of a disaster. In the event of a potential personal data breach, DAPs shall be responsible for determining whether a personal data breach has in fact occurred and, if so, providing breach notifications as required by law.

Patient consent

As this study does not involve data subject to privacy laws according to applicable legal requirements, obtaining informed consent from individuals is not required.

12 Management and Reporting of Adverse Events/Reactions

This study is a retrospective drug utilisation study of ASMs, and not a prospective clinical trial or cohort study. Thus, management and reporting of adverse events/reactions will not be relevant and not feasible within the scope of our used methodologies.

For studies in which the research team uses only data from automated EHDs, according to the International Society for Pharmacoepidemiology Guidelines for GPP:

“Aggregate analysis of database studies can identify an unexpected increase in risk associated with a particular exposure. Such studies may be reportable as study reports, but typically do not require reporting of individual cases. Moreover, access to automated databases does not confer a special obligation to assess and/or report any individual events contained in the databases. Formal studies conducted using these databases should adhere to these guidelines.”

For non-interventional study designs that are based on secondary use of data, such as studies based on medical chart reviews or electronic health records, systematic reviews, or meta-analyses, reporting of adverse events/adverse drug reactions is not required. Reports of adverse events/adverse drug reactions should only be summarized in the study report, where applicable.

According to the EMA Guideline on GVP, Module VI – Management and Reporting of Adverse Reactions to Medicinal Products,

“All adverse events/reactions collected as part of [non-interventional post-authorization studies with a design based on secondary use of data], the submission of suspected adverse reactions in the form of [individual case safety reports] is not required. All adverse events/reactions collected for the study should be recorded and summarized in the interim safety analysis and in the final study report.”

Module VIII – Post-Authorization Safety Studies echoes this approach. Legislation in the EU further states that for certain study designs such as retrospective cohort studies, particularly those involving electronic health records, it may not be feasible to make a causality assessment at the individual case level.

13 Plans for Disseminating and Communicating Study Results

As per EMA Good Pharmacovigilance Practices (GVP) Module VIII, the study and its protocol has been registered in the HMA-EMA Catalogues of RWD studies prior to the start of data collection.⁶⁶ Results of analyses and interpretation will be delivered in report form. Study results will be published following guidelines, including those for authorship, established by the ICMJE. When reporting the results of this study, the appropriate Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist and the RECORD-PE extension will be followed. Independent publication rights will be granted to the research team in line with Section VIII.B.5. Publication of study results, of the EMA GVP Module VIII: Post-Authorisation Safety Studies. Upon study completion and finalisation of the study report, the results of this study will be submitted for publication, preferably in a relevant peer-reviewed journal and posted in the HMA-EMA Catalogues of RWD studies. Also, study findings will be presented in national, regional and international conferences, when applicable. Analytical programs will be posted in a public GitHub & Zenodo repository after acceptance of the report. The study report will also be publicly posted on Zenodo (VAC4EU, EU PE&PV) and cross-linked to the HMA-EMA Catalogues of RWD studies.

14 References

1. Tomson T, Battino D, Perucca E. Teratogenicity of antiepileptic drugs. *Curr Opin Neurol*. 2019 Apr;32(2):246-252. doi: 10.1097/WCO.0000000000000659.
2. Bromley R, Adab N, Bluett-Duncan M, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. *Cochrane Database Syst Rev*. 2023 Aug 29;8(8):CD010224. doi: 10.1002/14651858.CD010224.pub3.
3. Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. *Cochrane Database Syst Rev*. 2014 Oct 30;2014(10):CD010236. doi: 10.1002/14651858.CD010236.pub2.
4. Xu SC, Zhong Y, Jiang HY, Tang J. Exposure to anti-seizure medication during pregnancy and the risk of autism and ADHD in offspring: a systematic review and meta-analysis. *Front Neurol*. 2024 Jul 22;15:1440145. doi: 10.3389/fneur.2024.1440145.
5. European Medicines Agency. New measures to avoid valproate exposure in pregnancy endorsed. 31 May 2018. EMA/375438/2018. Accessed 14 September 2024. Available from: https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_en-0.pdf.
6. European Medicines Agency. New measures to avoid topiramate exposure in pregnancy. 13 October 2023. EMA/455917/2023. Accessed 14 September 2024. Available from: https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_en.pdf
7. Leonardo Alves T, Hegger I, Almasdottir AB, et al. Impact of EU label changes and pregnancy prevention programme for medicinal products containing valproate and related substances: risk awareness and adherence. 2022. Registered protocol in EU PAS, EUPAS32405. Available from: <https://catalogues.ema.europa.eu/node/3449/administrative-details>
8. Abtahi S, Pajouheshnia R, Durán CE, et al. Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study. *Drug Saf*. 2023 Jul;46(7):689-702. doi: 10.1007/s40264-023-01314-3.
9. Jodicke A, et al. DARWIN EU® - Drug utilisation of valproate-containing medicinal products in women of childbearing potential. Registered protocol in EU PAS, EUPAS50789. Available from: <https://catalogues.ema.europa.eu/node/3650/administrative-details>
10. Degremont A, Polard E, Kerbrat S, et al. Impact of recommendations on sodium valproate prescription among women with epilepsy: An interrupted time-series study. *Epilepsy Behav*. 2021 Dec;125:108449. doi: 10.1016/j.yebeh.2021.108449.
11. Ehlken B, Nishikawa C, Kaplan S, et al. Effectiveness of risk minimization measures for valproate: a drug utilization study based on implementation of a risk minimization programme in Europe, analysis of data from the UK. *Curr Med Res Opin*. 2022 Mar;38(3):461-468. doi: 10.1080/03007995.2021.1997286.
12. Toussi M, Shlaen M, Coste F, et al. Effectiveness of risk minimisation measures for valproate: A drug utilisation study in Europe. *Pharmacoepidemiol Drug Saf*. 2021 Mar;30(3):292-303. doi: 10.1002/pds.5166.
13. Hughes JE, Buckley N, Looney Y, et al. Valproate utilisation trends among women of childbearing potential in Ireland between 2014 and 2019: A drug utilisation study using interrupted time series. *Pharmacoepidemiol Drug Saf*. 2022 Jun;31(6):661-669. doi: 10.1002/pds.5427.

14. Houben E, Benson RJ, Steegers EAP, Herings RMC. Twenty-year trends in the use of anti-seizure medication among pregnant women in the Netherlands. *Epilepsy Behav.* 2022 Feb;127:108549. doi: 10.1016/j.yebeh.2021.108549.
15. Cohen JM, Cesta CE, Furu K, et al. Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006-2016: A study in the five Nordic countries, United States, and Australia. *Pharmacoepidemiol Drug Saf.* 2020 Aug;29(8):913-922. doi: 10.1002/pds.5035.
16. Hurault-Delarue C, Morris JK, Charlton R, et al. Prescription of antiepileptic medicines including valproate in pregnant women: A study in three European countries. *Pharmacoepidemiol Drug Saf.* 2019 Nov;28(11):1510-1518. doi: 10.1002/pds.4897.
17. Leinonen MK, Igland J, Dreier JW, et al. Socioeconomic differences in use of antiseizure medication in pregnancies with maternal epilepsy: A population-based study from Nordic universal health care systems. *Epilepsia.* 2024 Aug;65(8):2397-2411. doi: 10.1111/epi.18022.
18. Knight R, Wittkowski A, Bromley RL. Neurodevelopmental outcomes in children exposed to newer antiseizure medications: A systematic review. *Epilepsia.* 2021 Aug;62(8):1765-1779. doi: 10.1111/epi.16953.
19. Cohen JM, Alvestad S, Suarez EA, et al. Comparative Risk of Major Congenital Malformations With Antiseizure Medication Combinations vs Valproate Monotherapy in Pregnancy. *Neurology.* 2024 Jan 23;102(2):e207996. doi: 10.1212/WNL.0000000000207996.
20. Bjørk MH, Zoega H, Leinonen MK, et al. Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. *JAMA Neurol.* 2022 Jul 1;79(7):672-681. doi: 10.1001/jamaneurol.2022.1269. Erratum in: *JAMA Neurol.* 2022 Jul 01;79(7):727. doi: 10.1001/jamaneurol.2022.1964.
21. Meador KJ, Cohen MJ, Loring DW, et al. Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study. *Lancet Neurol.* 2023 Aug;22(8):712-722. doi: 10.1016/S1474-4422(23)00199-0.
22. Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH. Teratogenic effects of antiepileptic drugs. *Expert Rev Neurother.* 2010 Jun;10(6):943-59. doi: 10.1586/ern.10.57.
23. Richy F, et al. A post-authorization safety study (PASS) to evaluate the paternal exposure to valproate and the risk of neurodevelopmental disorders including autism spectrum disorders as well as congenital abnormalities in offspring - a population-based retrospective study. Registered protocol in EU PAS, EUPAS34201. Available from: <https://catalogues.ema.europa.eu/node/3611/administrative-details>
24. European Medicines Agency. Potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines: PRAC recommends precautionary measures. 12 January 2024. Accessed 14 September 2024. Available from: <https://www.ema.europa.eu/en/news/potential-risk-neurodevelopmental-disorders-children-born-men-treated-valproate-medicines-prac-recommends-precautionary-measures>
25. Medicines and Healthcare products Regulatory Agency. Paternal exposure to valproate and risk of neurodevelopmental disorders and congenital malformations in offspring: Review of results from a Scandinavian post-authorisation safety study (PASS). Public Assessment Report. September 2024. Accessed 14 September 2024. Available from: https://assets.publishing.service.gov.uk/media/66d9ab24608fb761b6811130/Valproate-PAR-PASS_accessible_-_PUBLISH.pdf
26. Garey JD, Damkier P, Scialli AR, et al. Paternal Valproate Treatment and Risk of Childhood Neurodevelopmental Disorders: Precautionary Regulatory Measures Are Insufficiently Substantiated. *Birth Defects Res.* 2024 Aug;116(8):e2392. doi: 10.1002/bdr2.2392.
27. Christensen J, Trabjerg BB, Dreier JW. Valproate Use During Spermatogenesis and Risk to Offspring. *JAMA Netw Open.* 2024 Jun 3;7(6):e2414709. doi: 10.1001/jamanetworkopen.2024.14709.

28. Fortier I, Raina P, Van den Heuvel ER, et al. Maelstrom Research guidelines for rigorous retrospective data harmonization. *Int J Epidemiol*. 2017 Feb;46(1):103–5.
29. Brigo F, Lattanzi S. Anti-convulsant agents: benzodiazepines (clobazam, clonazepam, diazepam, lorazepam, midazolam). In *Neuro Psychopharmacotherapy* 2022 Nov 5 (pp. 3753-3760). Cham: Springer International Publishing.
30. Bryson A, Reid C, Petrou S. Fundamental neurochemistry review: GABAA receptor neurotransmission and epilepsy: principles, disease mechanisms and pharmacotherapy. *Journal of neurochemistry*. 2023 Apr;165(1):6-28.
31. Deeks ED. Mirogabalin: first global approval. *Drugs*. 2019 Mar 1;79(4):463-8.
32. Dima AL, Dediu D. Computation of adherence to medication and visualization of medication histories in R with AdhereR: Towards transparent and reproducible use of electronic healthcare data. *PLoS One*. 2017 Apr 26;12(4):e0174426. doi: 10.1371/journal.pone.0174426.
33. Christensen J, Trabjerg B, Dreier JW. Correlation of drug dose estimated from national prescription registers with mean blood level of antiseizure medication in pregnancy. *Pharmacoepidemiol Drug Saf*. 2024 Jun;33(6):e5811. doi: 10.1002/pds.5811.
34. Durán CE, Riera-Arnau J, Abtahi S, et al. Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis. *Front Pharmacol*. 2023 Aug 17;14:1207976. doi: 10.3389/fphar.2023.1207976.
35. Kadra G, Stewart R, Shetty H, et al. Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process. *BMC Psychiatry*. 2015 Jul 22;15:166. doi: 10.1186/s12888-015-0557-z.
36. Madley-Dowd P, Rast J, Ahlqvist VH, et al. Trends and patterns of antiseizure medication prescribing during pregnancy between 1995 and 2018 in the United Kingdom: A cohort study. *BJOG*. 2024 Jan;131(1):15-25. doi: 10.1111/1471-0528.17573.
37. Schachter SC, et al. Comorbidities and complications of epilepsy in adults. UpToDate. August 2024. Accessed 16 September 2024. Available from: <https://www.uptodate.com/contents/comorbidities-and-complications-of-epilepsy-in-adults>
38. Sánchez-Sáez F, et al. The Valencia Health System Integrated Database. First published: 01/02/2024. Available from: <https://catalogues.ema.europa.eu/node/1077/administrative-details>
39. García-Sempere A, Orrico-Sánchez A, Muñoz-Quiles C, et al. Data Resource Profile: The Valencia Health System Integrated Database (VID). *Int J Epidemiol*. 2020 Jun 1;49(3):740-741e. doi: 10.1093/ije/dyz266.
40. Recalde M, Rodríguez C, Burn E, et al. Data Resource Profile: The Information System for Research in Primary Care (SIDIAP). *Int J Epidemiol*. 2022 Dec 13;51(6):e324-e336. doi: 10.1093/ije/dyac068.
41. Duarte-Salles T, et al. The Information System for Research in Primary Care (SIDIAP). First published: 01/02/2024. Available from: <https://catalogues.ema.europa.eu/node/1019/administrative-details>.
42. Furu K, et al. Norwegian Health Registers. First published: 01/02/2024. Available from: <https://catalogues.ema.europa.eu/node/1074/administrative-details>.
43. Delmestri A, et al. Clinical Research Datalink (CPRD) GOLD. First published: 01/02/2024. Available from: <https://catalogues.ema.europa.eu/node/1026/administrative-details>.
44. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). *Int J Epidemiol*. 2015;44(3):827-836. doi:10.1093/IJE/DYV098.
45. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. *Br J Clin Pharmacol*. 2010 Jan;69(1):4-14. doi: 10.1111/j.1365-2125.2009.03537.x.

46. Herbert A, Wijlaars L, Zylbersztejn A, et al. Data Resource Profile: Hospital Episode Statistics Admitted Patient Care (HES APC). *Int J Epidemiol*. 2017;46(4):1093-1093i. doi:10.1093/IJE/DYX015.
47. Gissler M, Teperi J, Hemminki E, Meriläinen J. Data quality after restructuring a national medical registry. *Scandinavian journal of social medicine*. 1995 Mar;23(1):75-80.
48. Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. *Scandinavian journal of public health*. 2012 Aug;40(6):505-15.
49. Heino A, Niinimäki M, Mentula M, Gissler M. How reliable are health registers? Registration of induced abortions and sterilizations in Finland. *Informatics for Health and Social Care*. 2018 Jul 3;43(3):310-9.
50. Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A, Sørensen HT. Nordic health registry-based research: a review of health care systems and key registries. *Clinical epidemiology*. 2021 Jul 19:533-54.
51. Damase-Michel C, et al. EFEMERIS. First published: 01/02/2024. Available from: <https://catalogues.ema.europa.eu/node/1004/administrative-details>.
52. Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. *Eur J Clin Pharmacol*. 2009 Aug;65(8):839-46.
53. Maciá-Martínez MA, Gil M, Huerta C, et al. Base de Datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP): A data resource for pharmacoepidemiology in Spain. *Pharmacoepidemiol Drug Saf*. 2020 Oct;29(10):1236-1245. doi: 10.1002/pds.5006.
54. Macia M-A, et al. BIFAP- Base de Datos para la Investigación Farmacoepidemiológica en el Ámbito Público (Pharmacoepidemiological Research Database for Public Health Systems). First published: 01/02/2024. Available from: <https://catalogues.ema.europa.eu/node/955/administrative-details>.
55. Sanchez Ortiz S, Llorente García A, Astasio P, et al. An algorithm to identify pregnancies in BIFAP Primary Care database in Spain: Results from a cohort of 155 419 pregnancies. *Pharmacoepidemiol Drug Saf*. 2020 Jan;29(1):57-68. doi: 10.1002/pds.4910.
56. van Engeland H, et al. PHARMO Data Network. First published: 01/02/2024. Available from: <https://catalogues.ema.europa.eu/node/997/administrative-details>.
57. Kuiper JG, Bakker M, Penning-van Beest FJA, Herings RMC. Existing Data Sources for Clinical Epidemiology: The PHARMO Database Network. *Clin Epidemiol*. 2020 Apr 29;12:415-422. doi: 10.2147/CLEP.S247575.
58. Houben E, Broeders L, Steegers EAP, et al. Cohort profile: the PHARMO Perinatal Research Network (PPRN) in the Netherlands: a population-based mother-child linked cohort. *BMJ Open*. 2020 Sep 25;10(9):e037837. doi: 10.1136/bmjopen-2020-037837.
59. Thurin NH, Pajouheshnia R, Roberto G, et al. From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding. *Clin Pharmacol Ther*. 2022 Jan;111(1):321-331. doi: 10.1002/cpt.2476.
60. Royo AC, Elbers Jhj R, Weibel D, et al. Real-World Evidence BRIDGE: A Tool to Connect Protocol With Code Programming. *Pharmacoepidemiol Drug Saf*. 2024 Dec;33(12):e70062. doi: 10.1002/pds.70062.
61. Hoxhaj V, Navarro CLA, Riera-Arnau J, et al. INSIGHT: A Tool for Fit-for-Purpose Evaluation and Quality Assessment of Observational Data Sources for Real World Evidence on Medicine and Vaccine Safety. *MedRxiv* 2023.10.30.23297753; 30 Oct 2023. doi: 10.1101/2023.10.30.23297753v1 [Preprint].
62. Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). *Pharmacoepidemiol Drug Saf*. 2016;25(1):2–10.

63. Gini R, Fournie X, Dolk H, et al. The ENCePP Code of Conduct: a best practise for scientific independence and transparency in noninterventional postauthorisation studies. *Pharmacoepidemiol Drug Saf*. 2019;28(4):422–33.
64. Hurley E, Sturkenboom M, Nordeng H, CONSIGN consortium. COVID-19 infection and medicines in pregnancy – a multinational electronic health records/registry-based study. Zenodo; 2023.
65. Wang X, Chen C, Wang L, et al. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. *Fertil Steril*. 2003 Mar;79(3):577–84.
66. Abtahi S, Sturkenboom M, et al. The utilisation of antiepileptics in men and women of childbearing age, and pregnant women in Europe (ADEPT). HMA-EMA Catalogues of RWD studies. EU PAS number: EUPAS1000000212. First published: 17/06/2024. Available from: <https://catalogues.ema.europa.eu/node/4114/administrative-details>.
67. Hakami T. Neuropharmacology of Antiseizure Drugs. *Neuropsychopharmacol Rep*. 2021 Sep;41(3):336-351.
68. Corrales-Hernández MG, Villarroel-Hagemann SK, Mendoza-Rodelo IE, et al. Development of Antiepileptic Drugs throughout History: From Serendipity to Artificial Intelligence. *Biomedicines*. 2023 Jun 3;11(6):1632.
69. Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. *Lancet Neurol*. 2020 Jun;19(6):544-556.
70. Chou CC, Lin PT, Yen DJ, et al. Acute withdrawal of new-generation antiepileptic drugs in epilepsy monitoring units: Safety and efficacy. *Epilepsy Behav*. 2021 Apr;117:107846.